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Abstract 
In this dissertation, various glutarimide- and macrolactone-containing natural products are 
described in relation to their isolation, biological studies, and synthetic preparations. In particular, 
synthetic and biological studies on lactimidomycin (and related analogs) in regards to its 
previously reported activity as a cancer cell migration inhibitor compared to recently reporterd 
activity as a highly antiproliferic (cytotoxic) agent are discussed. 
Furthermore, the studies culminating in the total synthesis of the glutarimide-containing 
eukaryote translation elongation inhibitor lactimidomycin are described. The optimized synthetic 
route featured a Zn(II)-mediated intramolecular Horner-Wadsworth-Emmons (HWE) reaction 
resulting in a highly stereoselective formation of the strained 12-membered macrolactone of 
lactimidomycin on nearly a half gram scale. The synthetic route featured a late-stage installation 
of the glutarimide functionality via an asymmetric catalytic Mukaiyama aldol reaction, which 
allowed for a quick generation of an extended chain lactimidomycin homolog, which was tested 
in various biological assays alongside lactimidomycin and its truncated precursors. 
Finally, the biosynthetic origin, previous C-H modification, and synthetic studies towards 
isopimerane- and pimerane-containing natural diterpenes are discussed. The assymetric strategy 
towards a key chiral intermediate was achieved, establishing a highly scalable and convergent. 
Furthermore, previous studies along with preliminary model studies we have conducted 
demonstrated the feasibility of achieving a proposed key Michael-double reaction sequence to the 
core of isopimerane-containing natural products such as sphaeropsidin A and C, compactone, 
aspewentin A and B, and their derivitized analogs. 
 xxii 
 
Overall, the development of enantioselective routes to lactimidomycin, its structural 
analogs, and diterpene-type intermediates has successfully been accomplished.
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Chapter 1: Background and previous syntheses of select anticancer 
macrolactone- and glutarimide-containing natural products and analogs 
1.1 Introduction: natural products as a source of novel organic scaffolds 
The chemical synthesis of natural products is one of the important driving forces in the 
development of molecular medicine. However, the gaps in synthetic methodology represents a 
serious impediment to the discovery of new drugs.1-3 Natural products and their derivatives play 
an essential role in the drug discovery process, accounting for approximately 50% of the approved 
small-molecule-based drugs developed between 1981 and 2010.4 
There are still significant synthetic challenges in the production of large quantities of 
molecules with complex organic scaffolds in a rapid and scalable fashion. As complex and 
important natural products continue to be isolated and identified, the development and application 
of novel synthetic methodology to conduct shorter, simpler and more scalable routes is vital in 
accelerating the development and future production of new therapeutics.5 
1.2 Applications of total synthesis towards future anti-cancer therapeutics 
Despite current advancements in prevention and treatment, cancer remains one of the most 
dangerous and lethal diseases.6 One of the major factors responsible for the high mortality rate of 
various cancers is tumor metastasis, the spread of cancer from one organ or part of the body to 
another which is not directly connected. Therefore, developing new strategies to combat the spread 
of cancer could play a major role in reducing the number of deaths caused by it.7-10 More recently, 
natural product-based selective cancer cell migration (CCM) inhibitors have attracted significant 
attention from the scientific community due to their abilities to combat the progression of 
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metastasis, either by themselves or in combination with other therapeutic agents.9-24 
While it is true that semi-synthetic methods and biological approaches to these compounds 
and other anti-cancer therapeutics do exist, the best and sometimes only way to quickly access 
many natural product-based analogs to assess their biogical usefulness is through synthetic 
methods. Organic synthesis allows for a near infinite degree of compound derivatization in forming 
structural analogs, while semi-synthetic methology is currently limited in its capacity to which 
analogs can be accessed. It is vital for researchers to establish methods that are capable of rapidly 
synthesizing and accessing these types of compounds in order to aid in the development of novel 
pharmaceuticals, as demonstrated by previous successes of natural products in drug discovery.25 
1.3 Bioactive glutarimide-containing natural products 
The glutarimide-containing natural polyketides 1–8 (Figure 1.3.1 and Figure 1.3.2) have 
attracted considerable attention in biomedical research due to their potential application as anti-
cancer therapuetics.14, 20, 26-41 These natural compounds are typically isolated from bacteria,14, 26, 27, 
33, 42 and feature a glutarimide functionality attached to a linear (1-5) or a macrolactone (6-8) side-
chain. 
Figure 1.3.1: Linear glutarimide-containing natural products 
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Figure 1.3.2: Macrolactone- and glutarimide-containing natural products 
 
One of the most well-studied members of this family, cycloheximide (1), is routinely used a 
potent inhibitor of eukaryotic translation elongation; however, its dehydrated/aromatized 
counterpart, actiphenol (2) lacks this activity.33 While the glutarimide moiety generally represents 
the key biological element of these natural products, the macrolactone portion of these molecules 
has also found to be an important factor in the biological properties of some of these compounds.14, 
26-35 
1.4 Biosynthetic relationship of migrastatin, isomigrastatin, and dorrigocins A and B 
The presence of an unsaturated macrolactone in 6–8 significantly affects their stabilities. The 
Shen group has demonstrated that isomigrastatin 7 can be derived into shunt metabolites 8, 4, and 
5a, as well as 13-epi-dorrigocin A (5b) via an H2O-mediated rearrangement (Scheme 1.4.1).43 It 
was observed that the thermolysis of 7 in the presence of water resulted in an unprecedented [3,3] 
sigmatropic rearrangement/ring expansion that produced migrastatin (8). The macrolactone 
moieties of 7 and 8 are prone to hydrolysis, and the formation of 4, 5a, and 5b were also observed. 
Interestingly, the presence of an 8E-olefin in lactimidomycin (6) prevents this thermal 
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rearrangement, with no ring-expansion products detected for 6. However, the 12-membered 
macrolactone of lactimidomycin possesses significant ring strain and was found to undergo 
polymerization and decomposition upon storage in the neat state or when exposed to acids.44, 45 
 
Scheme 1.4.1: Derivatization of 7 into shunt metabolite 8 and the dorrigocins (4, 5a-b) 
1.5 Diverted total synthesis of migrastatin and its analogs 
Migrastatin (8) was first isolated from Streptomyces sp. MK929-43F1 and was found to 
possess modest tumor cell migration inhibitory activity.14 Many recent studies have focused on 
investigating the anticancer activity of 8, as this compound’s analogs were found to selectively 
and significantly inhibit cancer cell migration during the seminal work by Danishefsky and his 
group.20-23 Through their pioneering studies, they were able to accomplish the first total synthesis 
of migrastatin (8) and utilize a diverted total synthesis (DTS) to discover several analogs that 
contained impressive cell-migration inhibition activity. In particular, their DTS route allowed them 
to produce the simple and stable analogs 8a–8c, which display potent activity against breast cancer 
metastasis (Scheme 1.5.1). 
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Interestingly, these studies demonstrated that the glutarimide side-chain of 8 could be 
removed without affecting the antimetastatic activity of migrastatin. Subsequent in vivo work 
demonstrated that some of these analogs, in particular, 8a, could serve as potential selective and 
nontoxic inhibitors of various types of breast cancer metastasis.46-48 
 
Scheme 1.5.1: Migrastatin and related macrocyclic anticancer analogs 8a-8c 
1.6 Danishefsky’s total synthesis of isomigrastatin 
Isomigrastatin (7) was first isolated in 2002 as the main product from Streptomyces platensis 
strain NRRL18993.49 With promising reported biological activity, Danishefsky’s group quickly 
moved to develop a synthetic route.50 Their retrosynthetic plan involved a ring-closing metathesis 
of 9 to form the 12-membered macrolactone of 7, utilizing intermediates similar to their previous 
work on migrastatin (11-12) to lead to 10 and 9 (Scheme 1.6.1). 
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Scheme 1.6.1: Retrosynthetic analysis of isomigrastatin (7) 
 
Scheme 1.6.2: Synthesis of epoxy lactol intermediate 11 
The hetero-Diels Alder of known aldehyde 15 with known diene 16 proceeded using a 
catalytic amount of titanium tetrachloride, and removal of the TMS group with TFA gave the 
desired pyrone 17. Reduction with sodium borohydride and treatment with acid (Ferrier 
rearrangement) formed 18. Finally, the olefin was treated with m-CPBA to form the epoxy lactol 
11. 
Separately, the known glutarimide-containing aldehyde 19 was olefinated utilizing the 
known phosphanylidene 17 (Scheme 1.6.3). Compound 21 was hydrogenated using palladium on 
carbon to generate the functionalized Wittig reagent 12. 
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Scheme 1.6.3: Synthesis of the glutarimide-containing Wittig reagent 12 
A series of reduction, protection, and oxidation reactions were conducted to form the alcohol 23 
from 11. After oxidation to aldehyde 23, this compound could undergo the desired Wittig reaction 
with 12 to produce 24 (Scheme 1.6.4). 
 
Scheme 1.6.4: Synthesis of glutarimide-containing intermediate 23 
A diastereoselective reduction of the C-15 ketone (24) with the (S)-CBS catalyst, followed by TBS 
protection yielded 25 (Scheme 1.6.5). This TBS-protected alcohol functionality in 24 acted as a 
control element for the stereodirected ring-opening reaction with methylcuperate to proceed with 
good diastereoselectivity (13:1 dr, 83% yield) to form 26. As the macrocycle of 7 is known to be 
notoriously unstable due to the C2-C3 E-olefin (Scheme 1.4.1),43 it was seen best to hide this 
functionality to avoid issues of decomposition. A selenidoxide elimination was envisioned to do 
this, allowing introduction this olefin at a later stage. Furthermore, the absence of this olefin was 
predicted to help the RCM reaction proceed, rather than the direct formation of the highly-strained 
 8 
 
12-membered macrolactone of 7. Accordingly, esterification of 26 was done with 27 to provide 
the desired α-phenylselenoester 28. A routine series of deprotection/oxidation reactions were 
conducted on 28 to form RCM precursor 29 (Scheme 1.6.6). 
 
Scheme 1.6.5: Diastereoselective reduction, stereodirected addition with methylcuperate, 
and esterification reaction to transform 24 into 28 
 
Scheme 1.6.6: Synthesis of 29 and RCM reaction to form key macrocycle 30 and stereoisomer 
31 
The 2nd generation Grubbs’ catalyst was used to effect this ring-closing metastasis (RCM) to 
form 30 in only 2 minutes, but resulted in a lower than desired yield of the C6-C7 trans-olefin 
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product. In fact, a greater amount of the starting material was transformed into the undesired C6-
C7 cis-isomeric product, 31. 
The second E-olefin was introduced by subjecting 30 to m-CPBA, causing the predicted 
oxidative elimination of -SePh to install the C2-C3 trans-olefin of 7 (), finishing the first total 
synthesis of isomigrastatin (7). The spectroscopic data of the synthetic sample of 7 matched to the 
previously described data of its corresponding biologically isolated sample.49 
 
Scheme 1.6.7: Oxidative elimination of 29 to isomigrastatin (7) and isomerization of 7 to 32 
 Interestingly, while the oxidative elimination resulted in the desired C2-C3 E-olefin isomer, 
it was also observed that the compound was also forming the C2-C3 Z-olefin isomer, 32. This 
major decomposition route was determined to be driven by the thermodynamically favorable 
removal of ring strain via isomerization. This was demonstrated through the treatment of 7 to 
PMe3-catalyzed E-Z equilibrating conditions, which resulted in complete conversion of the 
material to the more stable isomer, 32. 
1.7 Lactimidomycin: A highly bioactive 12-membered macrolactone 
Lactimidomycin (6) is a glutarimide-containing natural product isolated by Sugawara et al. 
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in 1992 from Streptomyces amphibiosporus strain ATCC 53964 and reported to contain a variety 
of biological activities (antifungal, antibiotic, antiproliferative).26 Furthermore, Sugawara et al. 
demonstrated that 6 exhibits inhibitory activity against P388 leukemia tumors implanted in mice 
through observing the extended survival time of mice treated with the compound.26 
Initially, in vitro studies by the Shen group indicated that 6 strongly inhibits the migration of 
human MDA-MB-231 (IC50 = 0.6 nM) and mouse 4T1 (IC50 = 5.03 nM) mammary 
adenocarcinoma cells.51 In 2010, studies by the Liu group showed that lactimidomycin (6) is a 
strong inhibitor of eukaryotic translation elongation (IC50 = 38 nM);52 in other words, the antitumor 
activity from 6 may occur through blocking the translocation of the E-site of the 60S ribosomal 
subunit. Furthermore, they demonstrated that 6 had an appreciable effect on tumor growth of 
MDA-MB-231 breast cancer cells in vivo. In 2013,53 the Fürstner group found, in contrast to 
previous studies, lactimidomycin’s antiproliferic activity against certain cancer cell lines was even 
higher than previous reported, although his results are in conflict to the previous findings that 6 
can act as a CCM inhibitor in subtoxic doses.51 
This data suggests that lactimidomycin (6) is a potent anticancer agent, but its relatively high 
in vivo toxicity (lethal dose 32 mg/kg in mice),26 instability in solution,51 and conflicting reports 
of CCM inhibition activity51, 53 have significantly complicated the use of this natural product as an 
anticancer therapeutic. 
1.8 Fürstner’s first total synthesis of lactimidomycin 
In 2010, the Fürstner group published the first total synthesis of lactimidomycin.54 The route 
is notable in that it utilizes a unique ring-closing alkyne metathesis (RCAM) reaction to form the 
precursor to the strained 12-membered macrolactone ring.  
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Scheme 1.8.1: Fürstner’s retrosynthetic analysis of lactimidomycin (6) 
 
 
Scheme 1.8.2: Synthetic route to the alkyne intermediate 43 
Their initial proposal involved a retrosynthetic breakdown of the molecule into one of two 
RCAM precursors, 34 and 35 (Scheme 1.8.1). Both of these intermediates could be selectively 
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reduced into ketone 33, which they planned to attach the glutarimide functionality. 
First, a low-temperature mediated stereoselective alkylation of commercially available 36 
with MeI was performed, followed by a TES protection to form 37 (Scheme 1.8.2). Intermediate 
37 was reduced with DIBAL-H into its corresponding aldehyde, which was treated with a Wittig 
reagent to form 38. The material was submitted to another DIBAL-H reduction and was 
transformed into the aldehyde 39 via a PCC oxidation reaction. With the desired aldehyde in hand, 
39 was treated with the chiral auxiliary 40 to establish two new stereocenters, which was 
transformed into Weinreb’s amide 41. Compound 41 was reduced to its aldehyde form which could 
undergo a selective Julia coupling with 42 to form isomerically pure Z-enyne 43. 
 
Scheme 1.8.3: Key RCAM to the macrolactone 46 
With intermediate alcohol 43 in hand, they converted it to 44 via a Yamaguchi esterification 
reaction with 6-octynoic acid (Scheme 1.8.3). Next, they were able to successfully close the ring 
using catalyst 45 under high dilution conditions via a RCAM, resulting in yields of 84% and 95% 
on scales of 240 mg and 1.2 g, respectively, of the desired 12-membered enyne 46. 
This compound was treated with BnMe2SiH and [Cp*Ru(MeCN)3]PF6 followed by TBAF to effect 
a trans-hydrosilylation/protodesilyation, converting intermediate 46 into the alcohol 47 (), a key 
intermediate in every published formal and total synthesis of lactimidomycin (6). This compound 
was transformed to its lithium enolate form with LDA, which was quenched with PhSeBr to form 
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48. An oxidative elimination with m-CPBA yielded the desired C2-C3 unsaturated alcohol 49, 
another key intermediate. Oxidation of this alcohol 49 with DMP generated the ketone form, 33. 
 
Scheme 1.8.4: Late stage introduction of the C6-C7 and C2-C3 olefins in the formation of 
alcohol 49 and ketone 33  
Utilizing the ketone intermediate (33), the crude silyl enol ether form (50) was prepared 
(Scheme 1.8.5). 
 
Scheme 1.8.5: Completion of the total synthesis of 6 via a key chiral-catalyzed Mukiyama 
aldol reaction 
A chiral Mukiyama aldol reaction of 50 with aldehyde 19, in presence of chiral catalyst 51, 
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stereoselectively formed TMS-protected form of 6. This crude material was treated with buffered 
HF•pyridine complex and isolated via preparatory TLC to finish the first total synthesis of 
lactimidomycin (6). The synthetic 6 was formed in 60% yield over these 3 final steps, and its 
spectroscopic data matched with that of the previous literature.26, 51 
1.9 Fürstner’s studies towards lactimidomycin via RCM reactions 
Following this work, the Fürstner group published another paper demonstrating a formal 
total synthesis of 6. Following a similar approach to Danishefsky’s route to 7,50 they proposed to 
access the 12-membered macrolactone of 6 via a silyl-directed ring closing metathesis (RCM) 
reaction. Through the use of trisubstitued vinyl silane into the typical tetraene macrocyclization 
precursor, they hoped to increase the yields of the RCM reaction. The main focus of their work 
was to showcase the additional benefits of the vinyl silicon substituent in the field of metathesis in 
that it can act as both a protecting and stereochemical directing group for the formation of 
conjugated dienes; the bulky silyl group renders its olefin unreactive and also directs the newly 
formed olefin to the less hindered geometry. 
In a route similar to their previous one, but featuring a DMB protecting group this time,54 
aldol 52 was converted to aldehyde 55 through a known series of reactions (Scheme 1.9.1).55 
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Scheme 1.9.1: Transformation of aldol 52 into aldehyde 55 
With DMB-protected 55, they utilized the same series of reactions as before to reach 58. 
Two stereocenters with auxiliary 39¸ and then removed this auxiliary to form 56 (Scheme 1.9.2). 
 
Scheme 1.9.2: Synthesis of alkyne 58 
After protection with TES and DIBAL reduction to the aldehyde, they diverged significantly 
from their first generation approach, utilizing Ohira-Bestmann reagent 57 to form alkyne 58.56, 57 
The double protected diol 58 was submitted to a Sonagashira reaction to form 59 (Scheme 1.9.3).58 
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Scheme 1.9.3: Preparation of RCM precursor 62 with silyl directing group 
 
Scheme 1.9.4: Completion of the formal total synthesis via a vinyl-silane directed 
intramolecular E-selective RCM 
A series of steps were then used, including a regioselective hydrosilyation of 59 with 
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platinum complex 60 to form 61 (dr = 96:4, 93% yield), removal of the TES group, and 
esterification with 6-heptenoic acid to form the RCM precursor, 62. With intermediate 62 in hand, 
a variety of conditions were screened to optimize the intramolecular RCM reaction to 
preferentially promote formation of the C6-C7 E-olefin containing macrolactone 67 over its Z-
isomeric form 68 (Scheme 1.9.5). 
 
Scheme 1.9.5: Completion of the formal total synthesis via a vinyl-silane directed 
intramolecular E-selective RCM 
The hindered Dorta catalyst 66 was identified as superior to the other screened catalysts 
(63,59 64, and 65) in selectively bringing together the terminal olefins to form the C6-C7 E-olefin 
containing 67. This compound was then submitted to two deprotection steps, removing the DMB 
and silyl protecting groups, capturing intermediate 47 (Scheme 1.8.3) featured in their previous 
publication.54 
1.10 Scaled up synthesis of lactimidomycin (6)  
As previously detailed, two routes to lactimidomycin (6) were demonstrated by the Fürstner 
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group in 2010 and 2011, utilizing novel, but commercially unavailable catalysts (45, 66), and 
through late stage establishment of the α,β-unsaturated lactone functionality.54, 60 Following their 
previous work, an optimized protocol detailing the syntheses of 6 and 7 was published by Fürstner 
group in 2013.53 
First, acid 70 was prepared from β-ketoester 69 in 4 steps (Scheme 1.10.1). This acid was 
used to esterify intermediate 42 under Yamaguchi conditions61, 62 and form 72. The racemic form 
of 72 was produced with the reasoning that in eventually forming 49, this stereocenter would be 
lost upon elimination anyways. 
 
Scheme 1.10.1: Second generation RCAM-based methodology in the total synthesis of 
lactimidomycin 
Once again, the RCM precursor 72 lacked the C2-C3 olefin, in an effort to reduce ring strain 
and promote stability in the desired macrocycle 73. The alkyne functionality of 73 was transformed 
into the trans-olefin via the previously established 2-step hydrosilylation/desilylation protocol, 
which, in tandem, eliminated the C3-OBz functionality to form of the C2-C3 olefin. The resulting 
ketone intermediate 49 was formed and was confirmed to contain the fully functionalized 
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lactimidomycin macrolactone. This material was further transformed following the same 
methodology as before (Scheme 1.8.5),54 but on a much larger scale (138 mg, largest batch).63 
1.11 Diverted total synthesis: The second total synthesis of isomigrastatin (7) 
The key intermediate in the scaled up synthesis of lactimidomycin (Scheme 1.10.1), 
compound 73, could also be stereoselectively epoxidized into 75, which was converted into 76 via 
a methanolysis/deprotection sequence (Scheme 1.11.1). 
 
Scheme 1.11.1: Diverted total synthesis of 73 to isomigrastatin intermediate 77 
Intermediate 76 was subjected to a reduction/iodination sequence to form iodide 77, which 
was dehalogenated to form 78. Interestingly, the a DBU promoted elimination of the OBz group 
was initially tested on 77 and was found to inadvertently promote a ring-opening decomposition 
pathway into 78a, further demonstrating the inherent instability of these advanced macrocycle 
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intermediates (Scheme 1.11.2). 
 
Scheme 1.11.2: Base-catalyzed decomposition of the macrolactone-ring to acid 82 
Compound 78 was subjected previously employed conditions (Scheme 1.8.5) to attach the 
glutarimide side chain to form 79 (Scheme 1.11.3). 
  
Scheme 1.11.3: Completion of the diverted total synthesis to form isomigrastatin (7) 
 Intermediate 79 was treated to a condensation reaction, eliminating the alcohol functionality, 
followed by a selective hydrogenation with excess 80 to form 81. The ketone functionality of 81 
was unselectively reduced with sodium borohydride, and careful treatment with DBU eliminated 
the OBz group to form 82. Impressively, these DBU conditions did not promote the previously 
seen decomposition (Scheme 1.11.2), and a DMP oxidation of alcohol 82 completed the second 
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reported total synthesis of isomigrastatin (7). 
1.12 Biological results observed by the Fürstner group on 6, 7, and their analogs 
Furthermore, the Fürstner group synthesized a variety of macrolactone-based analogs, including 
83-85 (Scheme 1.12.1).53 
 
Scheme 1.12.1: Selected lactimidomycin (6) analogs with minor CCM inhibitory activity 
Unfortunately, both the analogs (83-85) and the natural products (6, 7) showed only minimal 
inhibition of migration at concentrations just below their one day cytotoxicity (IC50) values in the 
SWH Assay (Table 1.12.1).53 
Table 1.12.1: Minimal inhibition of migration of 4T1 cells in SWH assay observed 
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Interestingly, their complete biological studies indicated that lactimidomycin (6) and 
isomigrastatin (7) are much more potent in their antiproliferative (cytotoxic) activity against 4T1 
cells after one day and do not inhibit cancer cell migration in subtoxic doses for LoVo, MDA-MB-
231, and 4T1 cancer cell lines, unlike the results previously reported by the Shen group.51 
1.13 Kuwahara’s formal total synthesis of lactimidomycin 
Concurrently with our own report (Chapter 2),64 the Kuwahara group disclosed the formal 
total synthesis of lactimidomycin’s core alcohol via macrolactonization.65 In a similar fashion to 
the Danishefsky and Fürstner approaches, the macrocyclization required the protection of the Δ2-
olefin in the macrolactone via a C2-phenylselenide. This synthesis is important in that it 
demonstrates a highly optimized and convergent route using traditional synthetic methods. 
Retrosynthetically, Kuwahara’s group planned out their approach to 6 by breaking down the 
molecule, planning a key Yamaguchi macrolactonization of 86 followed by an oxidative 
elimination to form the key alcohol  close the 12-membered macrolactone of 6 (Scheme 1.13.1). 
 
Scheme 1.13.1: Kuwahara’s retrosynthetic analysis towards a formal total synthesis of 
lactimidomycin (6) 
The E,Z-diene containing macrolactonization precursor 86 was planned to be formed from 
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a Stille coupling of cis-vinyl iodide 87 and E-stannyl alcohol 88. Compound 87 could be formed 
from Fürstner’s aldehyde 89 which could arise from known intermediate 90; meanwhile, 
compound 88 could be formed from commercially available 4-pentyn-1-ol. 
 
Scheme 1.13.2: Synthesis of intermediate cis-vinyl iodide fragment 95 
Starting from the known ketene silyl N,O-acetal 91,66-71 a series of reactions was performed, 
including a vinylogous Lewis-acid promoted aldol reaction with acetaldehyde, TES protection, 
cleavage of the auxiliary to the aldehyde form, and treatment with ketene silyl S,O- acetal 92 in 
the presence of catalytic Sn(OTf)2 and chiral amine 93 in propionitrile to obtain thioester 94 
(Scheme 1.13.2).72 
Fukuyama reduction of 94 proceeded in almost quantitative yields to the aldehyde form, 
which could undergo a Z-selective Stork-Zhao olefination reaction (Z/E > 20:1) with the Wittig 
reagent to obtain 95.73 Next, they pursued the synthesis of the E-stannyl alcohol fragment 88 
(Scheme 1.13.3). Starting with 4-pentyn-1-ol, a palladium catalyzed syn-hydrostannation was used 
to form the known E-stannyl alcohol 96.74 Alcohol 96 was converted to its corresponding iodide 
via an Appel reaction, which was used to alkylate ethyl 2-(phenylseleno)acetate 97 to successfully 
form intermediate 88. 
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Scheme 1.13.3: Synthesis of E-stannyl alcohol fragment 88 
With fragments 87 and 88 in hand, a Stille coupling under Corey’s modified conditions was 
employeed to form the E,Z-diene containing 98 in great yield and selectivity75, 76 (Scheme 1.13.4). 
A selective deprotection of the TMS group was achieved under LiOH conditions to form seco-acid 
99. Finally, treatment with Yamaguchi lactonization conditions transformed 99 into intermediate 
100, followed by unmasking of the Δ2-olefin via an oxidative elimination, yielding the key 
intermediate alcohol 49. 
 
Scheme 1.13.4: Key Suzuki and Yamaguchi lactonization steps to complete formal total 
synthesis 
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Scheme 1.13.5: Poor-yielding direct cyclization into the C2-C3 unsaturated macrolactone 
Interestingly, they observed that cyclization of the TBS-protected, Δ2-olefin containing, 
seco-acid 101 provided only 22% of the macrolactone 102 (Scheme 1.13.5); in contrast, the 
previously described cyclization was significantly more efficient, giving 92% yield over the final 
two steps. 
1.14 Georg’s formal total synthesis of lactimidomycin (6) 
Recently, in 2015, Georg’s group published yet another formal total synthesis of 
lactimidomycin,77 further demonstrating the interest in the scientific community in forming these 
bioactive molecular scaffolds (Figure 1.3.2). They envisioned forming the lactimidomycin core 
using a method based on the Castro-Stephens coupling and an in situ alkyne reduction (Scheme 
1.14.1). 
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Scheme 1.14.1: Georg’s retrosynthetic analysis of lactimidomycin (6) 
 As there was no precedent for this reaction in having the olefin functionality next to the 
carbonyl preinstalled or later established, they proposed testing both seco acids (108, 109, Scheme 
1.14.2) in their key ring-closing step 
 
Scheme 1.14.2: Synthesis of unsaturated (108) and saturated (109) seco acids 
Acid 108 was formed by submitting iodo-alcohol 112 to a sequence of reactions, including 
a Swern oxidation, Wittig coupling, and tin-promoted ester cleavage (Scheme 1.14.2);78 acid 109 
was formed via Jones oxidation of known iodo-alcohol 113.79 With these fragments prepared they 
pursued the formal total synthesis, following a sequence reminiscent of previous routes 
transforming acid 114 into 115 (Scheme 1.14.3).80, 81 
 
Scheme 1.14.3: Synthesis of aldehyde 116 
Intermediate 115 underwent similar reactions as before, but was protected with a TBDPS 
silyl group, and after a DIBAL-H reduction, formed 116. Next, this intermediate was coupled with 
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a chiral allenylzinc reagent, which was formed in situ from (R)-but-3-yn-2-yl methanesulfonate, 
in a highly selective Marshall’s propargylation reaction to form alcohol 117 (Scheme 1.14.4). This 
alcohol could then undergo a Mitsunobu esterification reaction with acids 108 or 109 to form 118 
or 119, respectively, both with a small amount of diastereomeric material carrying through from 
the previous reaction. 
 
Scheme 1.14.4: Synthesis of ring-closing step precursors 118 and 119  
Finally, intermediates 118 and 119 were both submitted to the key ring closing methodology 
based on the Castro-Stephens coupling and in situ alkyne reduction (Scheme 1.14.5 and Scheme 
1.14.6, respectively). 
 
Scheme 1.14.5: Unsuccessful ring-closing coupling/in situ alkyne reduction of 118 to 120 
Surprisingly, 118 failed to produce any detectable amount of 120, while 119 yielded the 
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desired macrocycle product 121 in an 83% yield, further demonstrating the difficulty in forming 
this strained C2-C3 E-olefin containing 12-membered macrocyclic ring system directly. A final 
TBAF-mediated deprotection reaction yielded the key Fürstner intermediate 47, completing the 
formal total synthesis of 6. 
 
Scheme 1.14.6: Completion of the formal total synthesis of 6 by reaching the key saturated 
C2-C3 alcohol 47 
1.15 Summary of synthetic methodologies covered 
The following optimized key ring-closing steps in forming the 12-membered macrolactone 
during formal and total syntheses of 6 or 7 have been described (Scheme 1.15.1). The Danishefsky 
group utilized a late-stage ring-closing metathesis of 29 to close the 12-membered ring of 7 and to 
install the C6 trans-olefin. In order to facilitate the formation of the macrocycle, the ring strain in 
the RCM product 30 was reduced by masking the Δ2-olefin of 29 as the C2 selenide. This E-enoate 
functionality was re-installed later by subjecting 30 to oxidation with m-CPBA, thereby converting 
it into 7. 
Fürstner’s initial RCAM approach to 6 encountered oligermerization issues if the alkyne was 
present at the C8 position rather than the C6 position; therefore, a selective reduction was used to 
introduce the C6 olefin functionality after the key RCAM. The RCAM sequence was later 
optimized in 2013, establishing a unified approach to isomigrastatin (7) and allowing for a larger 
scale synthesis of lactimidomycin (6, 138 mg) to be achieved. This approach was based on ring-
closing alkyne metathesis of substrate 72 leading to 73. In a similar fashion to Danishefsky’s 
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synthesis of isomigrastatin, the RCM precursor 72 lacked the Δ2-olefin, reducing the ring strain in 
product 73. The alkyne functionality of 73 could undergo either a stereoselective epoxidation 
reaction, followed by a series of steps to convert it into isomigrastatin (7), or a 2-step 
hydrosilylation/desilylation protocol that also resulted in the elimination of the C3-OBz 
functionality and formation of the Δ2-olefin containing compound 33. 
Concurrently with our own report,64 the Kuwahara group described a formal total synthesis 
of lactimidomycin via the macrolactonization of seco acid 101 followed by oxidative elimination 
to form key alcohol intermediate 49; more recently, in 2015, another formal total synthesis has 
been reported by the Georg group in which 119 is submitted to conditions based on a Castro-
Stephens coupling and a tandem in situ alkyne reduction to form 121. 
These recent formal total synthesis papers provide excellent examples of the difficulties 
encountered in synthesizing the 12-membered macrolactone of 6 directly, containing three units 
of unsaturation. In particular, having the C2-olefin preinstalled during or prior to the ring-closing 
step appeared to significantly complicate attempted cyclizations: Kuwahara observed a 22% yield 
when attempting to directly cyclize 101 to 102 (Scheme 1.13.5), and Georg observed no reactivity 
at all in the cyclization reaction of 118 to 120 (Scheme 1.14.5). 
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Scheme 1.15.1: Summary of key ring-closing steps utilized in forming 12-membered 
macrolactones of 6 and 7 
1.16 Conclusion 
Among the previous synthetic studies towards lactomidomycin (6) and isomigrastatin (7), 
one of the most challenging problems appears to be the formation of their similar, strained 12-
membered macrocycle moieties. In all of these studies, post-assembly installation of the unit of 
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unsaturation at the C2-C3 position of the macrolactone was either required or would yield 
significantly more favorable results compared to direct cyclizations into the C2-C3 unsaturated 
forms. Ultimately, this issue provided an interesting synthetic challenge in designing a scalable 
route to lactimidomycin (6) in the process of developing novel, natural product based analogs of 
this natural product. 
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Chapter 2: Synthesis and biological evaluation of lactimidomycin and its 
analogs 
2.1 Background 
Due to its valuable biological and medicinal properties and potential for treatment of various 
cancers,1-8 we undertook designing a general and scalable synthetic approach to lactimidomycin 
(6). A synthetic approach to 6 and its analogs could aid in identifying new anticancer agents with 
improved stability and therapeutic properties; however, the high ring strain energy associated with 
the unsaturated 12-membered macrolactone of lactimidomycin significantly complicates the 
preparation of this macrolide. As a consequence, at the time our studies commenced (2010), only 
Danishefsky’s group route to isomigrastatin9 and Fürstner’s group’s initial approaches to 
lactimidomycin10, 11 could provide access to synthetic 6 and 7.12-14 Along with the initial report by 
the Shen group, which indicated that 12-membered glutarimide-containing macrolides 
lactimidomycin (6) and isomigrastatin (7) inhibited cancer cell migration in vitro,15 we were 
inspired to develop a scalable approach to 6 and its analogs. Although a following study by the 
Furstner group contradicted the findings of the Shen and coworkers,12 the initial studies showing 
that 6 can serve as a very potent antitumor agent, due to its ability to inhibit the translocation step 
in eukaryotic protein translation initiation, still made this an interesting target for biological 
studies.16-18 
 While there exists a few methods to generate these glutarimide-containing natural products 
6-7 via biological isolation,16, 19 formal11, 20, 21 and total synthetic means,10, 12 at the time of starting 
our research in 2010, none offered scalable and easily conductible route without commercially 
available catalysts and toxic reagents such as selenium or alkylated tin(IV) compounds; 
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furthermore, we envisioned a diverted total synthetic approach which would allow we to achieve 
the rapid formation of otherwise unreachable analogs of 6, and potentially 7. 
2.2 Research plan 
In developing a viable, general strategy to lactimidomycin (6), it was vital that the number 
of synthetic steps required after the formation of the macrocyclic ring were minimized, in order to 
avoid the decomposition and isomerization reactions of the synthetic intermediates.22-25 To 
accomplish this, we proposed to establish both the macrocyclization and installation of the Δ2-
enoate double bond in a single step through an intramolecular Horner-Wadsworth-Emmons 
(HWE) cyclization of protected precursor 122 (Scheme 2.2.1), eventually leading to the silyl enol 
ether 42 intermediate, after conducting the standard procedures previously described by Fürstner. 
This would then allow for a rapid, scalable route to the lactimidomycin (6) scaffold, allowing for 
the development of less toxic, more stable, and, more potent cancer cell migration inhibitors. 
As the synthesis of the E,Z-diene functionality represented one of the key challenges in the 
construction of precursor 122, several different approaches were envisioned. Thus, a Z-selective 
Witting reaction of 123 and 124,26 a cross metathesis reaction of 125 and 126 followed by a 
stereoselective Peterson elimination27 as well as a Suzuki cross-coupling of 139 and 140 were 
among the possibilities that we considered to investigate. 
This chapter summaries our studies on the stereoselective construction of various 
unsaturated 12-membered macrocycles and application of this strategy to the total synthesis of 
lactimidomycin (6). 
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Scheme 2.2.1: Full retrosynthetic analysis10, 12 
2.3 Model studies on the intramolecular HWE on the 12-membered macrocycle 
While intramolecular olefination reactions could be utilized for the construction of larger 
macrocycles, E-selective cyclizations leading to 12-membered macrolactones have little 
precedence.28, 29 In addition, the presence of the (E,Z)-diene moiety decreases the overall flexibility 
of the macrocycle, which could affect the relative rates for the intermolecular versus intramolecular 
pathways. To evaluate the feasibility of the approaches depicted in Scheme 2.2.1, we initiated 
another series of model studies with the unfunctionalized phosphonate 141 (Table 2.3.1). 
Intramolecular cyclization of 141 under standard conditions employing potassium carbonate (entry 
1)30 or lithium hexamethyldisilazide (entry 2)28 as bases did not result in the formation of 130 and 
only diolide 131 was isolated. Subjecting 141 to the standard Masamune-Roush olefination 
protocol (entry 3)31 provided only minor quantities of E-enoate 130 (13% yield) and mostly 
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resulted in diolide 131 (60% yield). Encouraged by these results we decided to evaluate other soft 
enolization conditions,32-35 surmising that the Lewis acidity of the counterion correlates with its 
ability to bring together the termini of 141. Gratifyingly, the combination of zinc (II) 
trifluoromethanesulfonate, TMEDA and trimethylamine36, 37 (entry 4) promoted the E-selective 
formation of the macrolactone 130 (78% yield) and only a minor quantity of diolide 131 was 
observed (9% yield). 
Table 2.3.1: Optimization of HWE-Macrocyclization 
  
Although Zn(II)-mediated macrocyclizations could be used to construct the lactimidomycin 
core, it was unclear whether this method could be applied to the preparation of other 12-membered 
macrocyclic systems such as the one of isomigrastatin (7). In order to understand the role of 6E- 
and 8Z- units of unsaturation, another series of studies were conducted. In addition to 141, 
phosphonates 132 with various degrees of unsaturation at the C6- and C8- positions were subjected 
to Zn(II)-mediated macrocyclizations (Table 2.3.2).i The removal of one of the olefins at either the 
 
i Experiments were conducted by Dr. Zhankui Sun. 
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C6- (entry 3) or C8- (entry 2) positions did not significantly affect the formation of the 12-
membered ring, and the corresponding products, 133-2 and 133-3, were obtained in 73% and 69% 
yields, respectively. Furthermore, the successful formation of (6E)-133-2 was remarkable in that 
it indicates this method could be applied for the preparation of isomigrastatin (7) macrolactone. 
The saturated substrate 132-4 lacking the diene moiety did not cyclize to produce a 12-membered 
ring 133-4, and the corresponding diolide 133-4a (see SI section) was isolated as the only product. 
It is noteworthy that due to the high ring strain of the E-olefin containing macrolactones 133-1 and 
133-2, these compounds were found to be unstable and could be easily polymerized upon storage 
in neat state.22 
Table 2.3.2: Investigating the scope of Zn(II)-mediated HWE-macrocyclization 
 
With these encouraging model study results in hand, the synthesis of lactimidomycin (6) was 
pursued next (Scheme 2.3.1). These studies commenced with the known vinylogous Mukaiyama 
aldol reaction of 134 and acetaldehyde to provide the corresponding aldol adduct (93% yield, 
>20:1 dr).38, 39 Protection of this adduct (TBSCl, DMAP, ImH) followed by reductive removal of 
the auxiliary (NaBH4, 84% yield, 2 steps) and Parikh-Doering oxidation of the resultant alcohol 
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provided aldehyde 135. Aldehyde 135 was then subjected to the Evans syn-selective aldol 
reaction40 with a chiral oxazolidinone 136 to provide the corresponding aldol adduct (>20:1 dr) 
that was converted to silyl ether 137 (79% yield, 2 steps). With compound 137 in hand, the 
approaches to the construction of the (E,Z)-diene outlined in Scheme 2 were investigated next. 
Thus, the chiral auxiliary of 137 was removed through the formation of a thioester (EtSLi, 83% 
yield), which was reduced by DIBAL-H to provide the corresponding aldehyde 138.41, 42 
 
Scheme 2.3.1: Initial steps to form the aldehyde precursor to the desired E-S diene 
When initially conducting the previously described route, the TES form (138b) of the 
aldehyde 138 was generated in a similar reaction sequence; later, the TMS form would be chosen 
as a selective deprotection of this silyl group was more easily achieved with the TMS derivative. 
Therefore, all initial attempts to form the E-Z diene are described in relation to using the TES-
containing aldehyde`138b. This compound was first subjected to a known Cr(II)-mediated 
allylation with (1-bromoallyl)trimethylsilane (Scheme 2.3.2).43, 44 The resultant anti-products 139 
were obtained in 72% yield and 1:1 diastereoselectivity. These products (139) were then subjected 
to a base-promoted stereoselective Peterson elimination resulting in the terminal diene 140 (>20:1 
d.r.). Diene 140 was subjected to the cross-metathesis with DMB-protected alkene 141 using 
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various Ru-based catalysts; however, despite the large reported yield, a complex mixture of 
products was observed. The NMR and mass-spectrometric analysis of these products indicated that 
a significant isomerization of the Z-diene took place and a mixture of dienes 132a was formed; in 
addition, significant formation of the inseparable truncated products 132b were also detected. 
 
Scheme 2.3.2: Early attempts to install the (6Z,8E)-diene functionality during the first 
generation synthesis of lactimidomycin 
These results indicate that both olefins of 140 are equally reactive under the cross metathesis 
conditions,25 and, to avoid this problem, the mixture of diastereomers (139) was directly subjected 
to the cross-metathesis conditions. However, the attempts to accomplish the cross metathesis of 
139 and 141 led only to dimerization of 141; no reaction of the starting 139 observed by crude 
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1HNMR. The reduced reactivity of 139 could be attributed to the steric hindrance exhibited by the 
allylic triethylsilyl group; however, the use of the Grubbs-Stewart catalyst,45 which is less sensitive 
to steric effects, did not result in the formation of the desired cross-metathesis products. In addition 
to the aforementioned studies, the possibility of executing (Z)-selective Wittig coupling with allylic 
phosphorane 143 and aldehyde 138b was investigated. This coupling was executed under the 
conditions employed by the Smith group in their synthesis of latrunculin A,26 and resulted in diene 
131 as a 1:1 mixture of EE and ZE dienes (49% yield). 
 
Scheme 2.3.3: Synthesis of cis-vinyl iodide (134) 
With little success achieved in the aforementioned studies, we pursued the assembly of the 
(E,Z)-diene moiety through a Suzuki cross-coupling strategy (Scheme 2.3.3). Thus, the TMS-
protected aldol adduct 137 was converted to a corresponding aldehyde that was transformed into 
vinyl iodide 145 via a Stork-Zhao olefination protocol (56% yield over 3 steps, 14:1 E:Z).46 
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Scheme 2.3.4: Synthesis of the DMB-protected alcohol/boronic acid fragment 135 
 With fragment 145 in hand, a protected cross coupling partner was identified, a DMB-
protected alcohol/boronic acid, 146 (Scheme 2.3.4). It was hypothesized that the DMB protecting 
group would be easy to remove in the presence of the potentially isomerizable E-Z diene. The 
protected boronic acid 146 was synthesized in 3 steps starting from pent-4-en-1-ol which could 
undergo a cross metathesis reaction with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane to form 
146a. Next, a DMB protection reaction of this material formed 146b in acceptable yields, and 
treatment with sodium periodinate in ammonium acetate produced the crude boronic acid 146. 
Iodide 145 was then coupled directly with the crude 146. It is known that vinyl iodides 
similar to 145 could undergo an intramolecular Heck cyclization, and that this pathway could be 
suppressed by an addition of thallium(I) ethoxide.47 Indeed, subjecting the mixture of 145 and 146 
to Pd(PPh3)4/TlOEt48 resulted in the rapid formation of the desired cross-coupling product 
containing the desired (E,Z)-diene functionality. 
 
Scheme 2.3.5: First generation cross-metathesis leading to the formation of the HWE 
precursor  
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 The TMS group of the cross-coupling product was removed under acidic conditions to 
provide compound 147 in 91% yield over 2 steps from 145. The alcohol functionality of 147 was 
acylated with dimethyl(2-chloro-2-oxoethyl)phosphonate, DMAP, and pyridine, and the DMB 
group was removed with DDQ to form alcohol 148. Finally alcohol 148 was converted into 
aldehyde 149 by Dess-Martin oxidation (36%, 3 steps). 
 
Table 2.3.3: Optimization of the suzuki cross-coupling reaction with DMB-free boronic acid 
 Considering that the phosphono-aldehyde 149 is the key precursor to the HWE 
macrocyclization, further optimizations were conducted to reduce the number of steps leading to 
this compound and, in particular, to deliver sufficient quantities of alcohol intermediate 148 
required for the completion of the synthesis and generation of the analogs. The approach to 148 
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previously depicted (Scheme 2.3.5) suffered from a low-yielding deprotection of the DMB 
protecting group, highly toxic TlOEt required as the base for the Suzuki coupling leading to 147 
as well as the difficulties in the preparation and purification of boronate 146. In order to avoid the 
aforementioned problems, the vinyl iodide 145 was directly converted to the phosphonate 150 and 
the cross-coupling of 150 with unprotected boronate 151 (available in 1 step from pent-4-yn-1-ol) 
was investigated (Scheme 2.3.3). 
In a similar fashion to the previously developed cross-coupling of 145 and 146 (Scheme 
2.3.5), the reaction of 150 and 151 cleanly provided the desired product 148 (89% yield) when 
TlOEt was employed as the base (entry 1). The possibility of substituting Tl(I) base with Ag(I) 
oxide was investigated next (entries 2–3). Although we observed that Ag2O can substitute TlOEt 
as the base (entries 2–3),49 the resultant product 148 was contaminated with the inseparable 
impurities (entry 2) or its formation was sluggish (entry 3). Finally, in the search for the alternative 
conditions (entries 4 and 5),50, 51 the conditions previously developed by the Tan group52 cleanly 
resulted in the formation of 148 (entry 5) on both a small (100 mg) and large (900 mg) scale. 
Remarkably, no saponification of the ester functionality of 150 or 148, intramolecular Heck 
reaction of 150 or isomerization of the Z-vinyl iodide moiety of 150 was observed under these 
conditions. 
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Scheme 2.3.6: Optimized synthesis of lactimidomycin (6) 
With a robust synthetic route to macrocyclization precursor 149 developed, the possibility 
of the formation of lactimidomycin macrolactone using the Zn(II)-mediated intramolecular HWE 
reaction conditions determined previously (Table 2.3.1) was investigated. Remarkably, this 
cyclization proceeded with high yields and diastereoslectivity and resulted in the desired (E)-102 
(93% yield), with only minor quantities of the corresponding diolide observed (ca. 3% yield). This 
cyclization was executed on a large scale to provide 423 mg of 149 without erosion in the yield or 
selectivity (vide infra). The formal total synthesis of lactimidomycin was completed by TBS-group 
deprotection that resulted in alcohol 49 (90% yield), a key intermediate in Furstner’s syntheses of 
lactimidomycin.24, 53 The 1H and 13C NMR spectra as well as the optical rotation of 49 ([α]D = –
234, c = 1.16, CHCl3) matched the previously published physical characteristics ([α]D = –233, c = 
1, CHCl3). 
This compound was then elaborated to lactimidomycin following the previously published 
route.24, 53 Thus, 49 was oxidized to produce unstable ketone 33, which was observed to decompose 
 52 
 
in the neat state upon prolonged storage. Ketone 33 was also found to be unstable to multiple 
purifications by column chromatography and to traces of DCl in CDCl3. The methyl ketone 
functionality of 33 was converted into the corresponding silyl enol ether 50 (LiHMDS, Et3N, 
Me3SiCl). Without purification, 50 was subjected to the Mukaiyama aldol addition reaction with 
aldehyde 19 catalyzed by chiral oxazaborolidinone 93 (100 mol%, EtCN, –78 ºC). The resultant 
aldol adduct was treated with buffered HF•Py solution in pyridine/THF to remove the 
trimethylsilyl ether and produce lactimidomycin (6). In addition to 6, the silyl enol ether 50 was 
reacted with the homologous, 4-carbon chain, glutarimide-containing aldehyde 151 (Scheme 
2.3.7), resulting in the formation of the extended chain analog (ECA) of lactimidomycin (152), 
which contained two additional carbons between the glutarimide side-chain and macrolactone 
moieties. 
 
Scheme 2.3.7: Synthesis of extended (4-carbon) chain glutarimide aldehyde (55) 
2.4 Optical rotation confirmation of the formation of lactimidomycin (6) 
The 1H and 13C NMR data of the synthetic lactimidomycin were in good accordance with 
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those previously reported by the Shen54 and Fürstner24, 53 groups. However, the optical rotation 
value for synthetic 6 ([α]D = –20, c = 0.25, DMSO) was consistent with the corresponding value 
reported by the Sugawara group ([α]D = –20, c = 0.5, DMSO),16 but varied from the optical rotation 
values of Shen ([α]D = +23, c = 0.52, DMSO),55 and Fürstner ([α]D = +6.9, c = 0.5, DMSO)24, 53 
groups. In contrast, the CD spectrum of synthetic 6 was in good agreement with the corresponding 
spectrum of the natural sample.56 
The discrepancies in the optical rotation could be attributed to the presence of optically 
active impurities that arise from the decomposition of lactimidomycin. Consistent with our 
observations for macrolactone 29 as well as with our previous studies, 6 is unstable and could  
Decompose upon storage in the neat state (vide supra). 
2.5 Biological activity 
Table 4. In vitro evaluation of the anticancer activity and toxicity of lactimidomycin (6) and its 
analogues 102, 49, 33, and 153. 
 
 
 
[a] Obtained by dilution of the stock solution of the tested compound in DMSO with physiological 
buffer (cf. SI). MDA-MB-231 = human mammary adenocarcinoma cells; HMEC = human 
mammary epithelial cells; GI50 = 50% growth inhibition (cf. SI); TI = GI50 HMEC / GI50 MDA-
MB-231 3D. 
 
Lactimidomycin (6) and its analogs (102, 49, 33, 153) were next evaluated for their ability 
to slow the proliferation of a triple-negative breast cancer cell line (MDA-MB-231) previously 
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demonstrated to be growth inhibited by lactimidomycin (Table 4).[5] In addition to 2-dimensional 
cell culture on polystyrene, the anti-migration activity of each compound was evaluated in a 3-
dimensional cell culture model using basement membrane extract. Consistent with previous 
reports, lactimidomcyin (6) is a potent inhibitor of MDA-MB-231 cell proliferation and migration 
(Table 4). It is worth noting that lactimidomycin (6) does not display enhanced anti-migration 
activity compared to its anti-proliferative activity, which is in accordance with the observations 
made by Fürstner and coworkers.[5] The truncated analogs that are devoid of the glutarimide side 
chain (102, 49, 33) have significantly weaker anti-proliferative and anti-migration activities 
compared to lactimidomycin (6). Analog 153, with an increased linker length between the 
glutarimide side chain and macrolactone, has modest activity in both assays.  
To discriminate between selective anti-cancer activity and general cell cytotoxicity, the 
proliferation of primary, low passage human mammary epithelial cells (HMEC) was evaluated in 
the presence of each compound. Lactimidomycin (6) has highly potent anti-proliferative activity 
against this non-cancer cell line (Table 4). This result also suggests that the anti-cancer activity 
observed with lactimidomycin (6) is due to general cell cytotoxicity. The analogs (50–52, 55) were 
also examined for their activities against HME cells and were found to be modestly anti-
proliferative (Table 4). The use of a primary non-cancer cell line enables the calculation of a 
therapeutic index (TI = GI50 HMEC / GI50 MDA-MB-231 3D) for each compound. 
Lactimidomycin (6) has a very poor therapeutic index (<0.002), demonstrating higher activity in 
a healthy cell compared to the cancer cell. The analogs (102, 49, 33, 153), however, have 
significantly improved therapeutic indices (Table 4). For example, the extended chain analog (153) 
has a therapeutic index that is 275-fold higher than that of lactimidomycin (6). While this 
impressive improvement is attributed to the addition of two methylene spacers between the 
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glutaramide side chain and the macrolactone, it should be noted that the biological profiles of 153 
and 49, which lacks the glutarimide moiety, are similar.   
Together, these results raise questions about the promise of lactimidomycin (6) as a potential 
anti-cancer therapeutic, but indicate that analogs of lactimidomycin have the potential to be 
selective anti-cancer inhibitors. These results may also suggest a difference in the mechanism of 
action for lactimidomycin (6) and its analogs (102, 49, 33, and 153) in analogy to migrastatin 
case.[1d,2,3] Prior studies highlight the importance of the glutarimide moiety for the inhibition of the 
eukaryotic ribosome,[1j,1k] and the mechanism, by which the analogs lacking the glutarimide side-
chain (102, 49, 33) is yet to be clarified. 
Conclusions 
In summary, a scalable enantioselective approach to eukaryotic translation elongation and 
cancer cell migration inhibitor, lactimidomycin (6)57 as well as its extended chain analog 55ii have 
been developed. These syntheses feature Zn(II)-mediated E-selective Horner-Wadsworth-Emmons 
reaction to construct the strained 12-membered macrolactone of 6. 
 
Scheme 2.5.1: Key high-yielding, scalable intramolecular HWE ring-closing step in the route 
to lactimidomycin (6) 
 
ii Manuscript submitted Sept. 3rd, 2015: Brian J. Larsen, Zhankui Sun, Eric Lachacz, Iaroslav 
Khomutnik, Matthew B. Soellner* and Pavel Nagorny* “Synthesis and biological evaluation of 
lactimidomycin and its analogs,” Chemistry – A European Journal. 
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The macrocyclization reaction was found to be sensitive to the backbone unsaturation, which 
is important for restricting the conformational flexibility of macrocyclization precursors. The 
synthetic route features a late-stage installation of the glutarimide functionality via an asymmetric 
catalytic Mukaiyama aldol reaction, which allows for a quick generation of lactimidomycin 
homolog with two additional carbons in the glutarimide side chain. Similarly to lactimidomycin, 
this analog was found to possess cytotoxicity against MDA-MB-231 breast cancer cells (GI50 = 1–
3 μM). This activity was found to be similar to the activities of lactimidomycin precursor lacking 
the glutarimide moiety (GI50 = 1–3 μM). Although lactimidomycin was found to be the most potent 
in terms of anti-cancer activity, 152 as well as truncated analogs lacking the glutarimide side-chain 
were found to be significantly less toxic against human mammary epithelial cells. 
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Chapter 2: Supporting Information 
2.6 General reaction methods 
All reactions were carried out under an atmosphere of nitrogen in flame– or oven–dried 
glassware with magnetic stirring, unless otherwise noted. Air–sensitive reagents and solutions 
were transferred via syringe or cannula and were introduced to the apparatus through rubber septa. 
Intermediates used in water sensitive reactions were azeotroped in toluene or benzene prior to use. 
Reactions were cooled via external cooling baths: ice water (0 °C), dry ice–acetone (-78 °C), or 
Neslab CB 80 immersion cooler (-20 to -78 °C). Heating was achieved by use of a silicone bath 
with heating controlled by an electronic contact thermometer. Deionized water was used in the 
preparation of all aqueous solutions and for all aqueous extractions. Solvents used for extraction 
and flash column chromatography were ACS or HPLC grade. Reagents were purified prior to use 
following the guidelines of Perrin and Armarego.58 Tetrahydrofuran (THF), dichloromethane 
(DCM), toluene and diethyl ether (Et2O) were filtered through a column (Innovative Technologies) 
of activated alumina under nitrogen atmosphere. Chloroform (CHCl3) and deuterated chloroform 
(CDCl3) were filtered through a column of basic alumina and magnesium sulfate prior to use with 
acid sensitive materials. Purification of the reactions mixtures was performed by flash column 
chromatography using SiliCycleSiliaFlash P60 (230-400 mesh) silica gel. 4Å molecular sieves 
were pre-activated before use. 
2.7 Spectral data acquisition 
1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 
MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400-401 MHz) spectrometers and 
chemical shifts (δ) are reported in parts per million (ppm) with solvent resonance as the internal 
standard (CDCl3 at δ 7.26, C6D6 at δ 7.15). Data are reported as follows (s = singlet, br s = broad 
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singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, ddd 
= doublet of doublet of doublets, dddd = doublet of doublet of doublet of doublets, dqd = doublet 
of quartet of doublets, t = triplet, q = quartet, qd = quartet of doublets, m = multiplet; coupling 
constant(s) in Hz; integration). Proton-decoupled 13C NMR spectra were recorded on Varian vnmrs 
700 (175 MHz), Varian vnmrs 500 (125-126 MHz), Varian INOVA 500 (125-126 MHz) or Varian 
MR400 (100 MHz) spectrometers and chemical shifts (δ) are reported in ppm with solvent 
resonance as the internal standard (CDCl3 at δ 77.000, C6D6 at δ 127.683). High resolution mass 
spectra (HRMS) were recorded on MicromassAutoSpecUltima or VGtd (Micromass) 70-250-S 
Magnetic sector mass spectrometers in the University of Michigan mass spectrometry laboratory. 
Infrared (IR) spectra were recorded as thin films on NaCl plates on a Perkin Elmer Spectrum BX 
FT-IR spectrometer. Absorption peaks were reported in wavenumbers (cm-1). Optical rotations 
were measured in a solvent of choice on a JASCO P-2000 or Autopol III digital polarimeter at 589 
nm (D-line) and reported as follows: [α]TEMPD (c = g/100 mL, solvent). Circular Dichroism was 
measured in spectroscopic grade ethanol on a JASCO J-815 Circular Dichroism Spectrometer. 
2.8 General biological methods  
Cell growth inhibition assays: WST-1 reagent was obtained from Roche Applied Science. 
The cell proliferation colorimetric assay using WST-1 was performed according to 
manufacturer’s procedure.iii 
Cell Culture and Seeding Procedure: Cells were dispersed from flasks and collected by 
centrifugation (200xg for 5 minutes at rt). An aliquot of the resuspended cells was mixed with 
trypan blue solution and the cell number was quantified using a hemacytometer. In general, 
depending on the growth rate of the untreated cells, the cells were plated at 5.0 – 7.5 x 103 cells 
 
iii https://cssportal.roche.com/LFR_PublicDocs/ras/11644807001_en_11.pdf 
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per well. The cells were plated into sterile, clear bottom 96 well plates and cultured under normal 
growth conditions overnight prior to dosing with compound. 
Dosing: 100% DMSO compound stocks were prepared to 100X the final concentration 
desired in the assay. 3 µL of the DMSO stock solution was then added to 297 µL of the cell growth 
media to give a DMSO concentration of 1%. The cell media was removed by aspiration for 
adherent cells and replaced with 100 µL per well of the cell growth media containing the 
compound. In general, each compound concentration was dosed in triplicate wells. 
Assay: After the dosing period (72 hours) was complete, the plates were removed from the 
incubator and 10 µL per well of WST-1 reagent was added. The plates were returned to the 
incubator and incubated for 1 h, followed by shaking on a plate shaker for 60 seconds prior to the 
absorbance read (450 nm) on a BioTek Synergy 4 multimode plate reader. 
Data Analysis: The reference absorbance reading was subtracted from the formazan 
absorbance at 690 nm (background control well no compound added, 1% DMSO) and the data 
was plotted as a percentage of the vehicle (1% DMSO alone). Data analysis and curve fitting was 
performed using Graphpad Prism. For each cell line, there were n = 3 data points for each 
concentration. Each dose response curve was performed at least thrice, providing n ≥ 9 for each 
data point. 
3D cell culture: Prior to plating cells, 50 μL Cultrex basement membrane extract BME, 
Trevigen) was added to each well of a 96-well plate incubated on ice and then allowed to gel 
(cushion formation) over a 30-minute time period in a 37 °C  incubator. Cells (MDA-MB-231) 
were then dispersed from flasks and collected by centrifugation (200xg for 5 minutes at rt). An 
aliquot of the resuspended cells was mixed with trypan blue solution and the cell number was 
quantified using a hemacytometer. 100% DMSO compound stocks were prepared to 100X the final 
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concentration that is desired in the assay. 3 μL of the DMSO stock solution was then added to 297 
μL of the cell suspension supplemented with 5% BME to give a DMSO concentration of 1%. The 
cells were plated at about 1.0 x 104 cells per well (100 μL/well) in triplicate for each compound 
concentration.  
2.9 Optimization of HWE-macrocyclization (procedures & analytical/spectral data) 
 
Scheme 2.9.1: Synthesis of (4E,6Z)-9-((tert-butyldimethylsilyl)oxy)nona-4,6-dien-1-ol (129a) 
(Z)-tert-butyl((4-iodobut-3-en-1-yl)oxy)dimethylsilane59 (312 mg, 1.0 mmol) and (E)-(5-
hydroxypent-1-en-1-yl)boronic acid60 (195 mg, 1.5 mmol) were added to THF (5 mL). 
Pd(dppf)Cl2·DCM (33 mg, 0.04 mmol) and NaOH (1.0 M, 3 mL) were added. The mixture was 
stirred at rt for 15 h and then diluted with water and extracted with EtOAc. The combined organic 
layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The mixture 
was purified by flash column chromatography (hexanes/EtOAc, 80/20) to provide the diene 
compound 129a (242 mg, 89% yield). 1H NMR (400 MHz, CDCl3) δ 6.36 – 6.29 (m, 1H), 6.00 (t, 
J = 10.8 Hz, 1H), 5.70 – 5.63 (m, 1H), 5.35 – 5.30 (m, 1H), 3.66 – 3.60 (m, 4H), 2.40 – 2.35 (m, 
2H), 2.18 (q, J = 6.8 Hz, 2H), 1.70 – 1.63 (m, 2H), 0.87 (s, 9H), 0.04 (s, 6H). 13C NMR (125 MHz, 
CDCl3) δ 134.0, 130.1, 126.3, 126.1, 62.8, 62.5, 32.2, 31.5, 29.1, 25.9, 18.4, -5.3; HRMS (ESI) 
m/z calcd for C15H31O2Si+ [M+H]+ 271.2088, found 271.2090. IR (thin film, cm-1) 3333, 2929, 
1472, 1255, 1097. 
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Scheme 2.9.2: Synthesis of dimethyl (2-chloro-2-oxoethyl)phosphonate 
2-(Dimethoxyphosphoryl) acetic acid (840 mg, 5.0 mmol) and DMF (0.1 mL, 1.3 mmol) 
were added to DCM (10 mL). Oxalyl chloride (1.27 g, 10.0 mmol) was added slowly. The mixture 
was stirred at rt for 30 min before the solvent was removed in vacuo. Freshly synthesized acyl 
chloride, dimethyl (2-chloro-2-oxoethyl)phosphonate, was dried under high vacuum for 2 h before 
it was used in subsequent reactions. 
 
Scheme 2.9.3: Synthesis of (3Z,5E)-9-hydroxynona-3,5-dien-1-yl 2-
(dimethoxyphosphoryl)acetate (129e) 
The diene 129a (242 mg, 0.90 mmol) was added to DCM (10 mL). Next, 3,4-dihydropyran 
(126 mg, 1.5 mmol) and p-toluenesulfonic acid (8.6 mg, 0.05 mmol) were added. The mixture was 
stirred at rt for 30min. TLC showed complete reaction. DCM (40 mL) was added. The mixture was 
washed with saturated NaHCO3 and brine, dried over MgSO4, filtered, and concentrated in vacuo 
to give the crude product 129b. 
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The crude product 129b was added to THF (10 mL). TBAF (1.5 mL, 1 M in THF) was 
added. The mixture was stirred at rt for 3 h. TLC showed complete reaction. The solvent was 
removed in vacuo. DCM (40 mL) was added. The mixture was washed with brine, dried over 
MgSO4, filtered, and concentrated in vacuo. The mixture was purified by flash column 
chromatography (hexanes/EtOAc, 70/30) to provide compound 129c (188 mg), which was used 
immediately in the next reaction. 
The mono protected diol 129c (188 mg, 0.78 mmol) was dissolved in DCM (10 mL). Et3N 
(1.6 mmol, 162 mg) was added. The freshly prepared dimethyl (2-chloro-2-oxoethyl)phosphonate 
(296 mg, 1.6 mmol) in DCM (2 mL) was added slowly. The mixture was stirred at rt for 2 h. TLC 
showed complete reaction. DCM (40 mL) was added to the mixture. The mixture was washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo to give the crude product 129d which 
was used directly in the next step. 
The crude product 129d was added to MeOH (5 mL). p-Toluenesulfonic acid (17.2 mg, 0.1 
mmol) was added. The mixture was stirred at rt for 1 h at which point TLC showed the reaction 
had gone to completion. The solvent was removed in vacuo. DCM (40 mL) was added. The mixture 
was washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude product 
was purified by flash column chromatography (100% EtOAc) to provide compound 129e (187 mg, 
68% yield over 4 steps). 1H NMR (400 MHz, CDCl3) δ 6.35 – 6.28 (m, 1H), 6.06 (t, J = 10.8 Hz, 
1H), 5.75 – 5.69 (m, 1H), 5.29 – 5.26 (m, 1H), 4.15 (t, J = 6.8 Hz, 2H), 3.80 (d, J = 11.6 Hz, 6H), 
3.65 (t, J = 6.4 Hz, 2H), 2.95 (d, J = 21.6 Hz, 2H), 2.54 – 2.49 (m, 2H), 2.19 (q, J = 7.2 Hz, 2H), 
1.73 (br, 1H), 1.70 – 1.63 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 165.6 (d, J = 5.7 Hz), 135.2, 
131.3, 125.7, 123.8, 64.9, 62.1, 53.2(d, J = 6.2 Hz), 33.9, 32.8, 32.0, 29.0, 27.0; 31P NMR (200 
MHz, CDCl3) δ 22.5; HRMS (ESI) m/z calcd for C13H24O6P+ [M+H]+ 307.1305, found 307.1309. 
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IR (thin film, cm-1) 2921, 1734, 1261, 1030. 
 
Scheme 2.9.4: Synthesis of (3E,7E,9Z)-oxacyclododeca-3,7,9-trien-2-one (130) 
Phosphono-alcohol 129e (50 mg, 0.16 mmol) was added to DCM (5 mL). To this, Dess-
Martin periodinane (80 mg, 0.18 mmol) was added. The mixture was stirred at rt for 30 min before 
it was diluted with DCM (20 mL) and 1 mL of a 1:1 mixture of saturated NaHCO3 and 2.0% aq. 
Na2S2O3. The mixture was stirred vigorously for 5 min (until the organic phase was clear) and the 
phases were separated. The organic phase was dried over MgSO4, filtered, and concentrated in 
vacuo to yield phosphono-aldehyde 129, which was used directly in the next step. 
Tetramethylethylenediamine (0.036 mL, 0.24 mmol) and triethylamine (0.112 mL, 0.8 
mmol) were added to a suspension of Zn(OTf)2 (203.7 mg, 0.440 mmol) in THF (80 mL) at rt. The 
mixture was stirred for 15 min before phosphono-aldehyde 129 in THF (20 mL) was added drop-
wise over 1 h by syringe pump. The resulting mixture was stirred for 15 h at rt. TLC showed 
complete reaction. The reaction mixture was concentrated to 5 mL. The residue was diluted with 
ethyl acetate (100 mL) and washed with brine (20 mL). The organic phase was dried over MgSO4, 
filtered, and concentrated in vacuo to afford a clear oil that was purified by flash column 
chromatography (hexanes/EtOAc, 90/10) to afford compound 130 (22.7 mg, 78% for two steps). 
1H NMR (400 MHz, C6D6) δ 6.35 – 6.27 (m, 1H), 6.01 (t, J = 10.8 Hz, 1H), 5.65 (dd, J = 16.0, 
10.8 Hz, 1H), 5.40 (d, J = 16.0 Hz, 1H), 5.14 – 5.07 (m, 1H), 5.00 – 4.95 (m, 1H), 4.05 – 4.02 (m, 
2H), 2.02 – 2.00 (m, 2H), 1.68 – 1.63 (m, 4H). 13C NMR (125 MHz, C6D6) δ 166.4, 147.0, 133.7, 
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130.9, 128.1, 127.9, 125.8, 63.2, 31.8, 30.8, 27.6; HRMS (ESI) m/z calcd for C11H15O2+ [M+H]+ 
179.1067, found 179.1062. IR (thin film, cm-1) 2926, 1722, 1644, 1184, 1148. 
 
Scheme 2.9.5: Synthesis of hex-5-en-1-yl 2-(dimethoxyphosphoryl)acetate (132-2a) 
Hex-5-en-1-ol (250 mg, 2.5 mmol) was dissolved in DCM (20 mL). Et3N (5.0 mmol, 505 
mg) was added. Freshly prepared dimethyl (2-chloro-2-oxoethyl)phosphonate (930 mg, 5.0 mmol) 
in DCM (5 mL) was added slowly. The mixture was stirred at rt for 2 h. TLC showed complete 
reaction. The mixture was washed with brine, dried over MgSO4, filtered, and concentrated in 
vacuo. The mixture was purified by flash column chromatography (hexanes/EtOAc, 50/50) to 
provide compound 132-2a (562 mg, 89% yield). 1H NMR (400 MHz, CDCl3) δ 5.59 – 5.54 (m, 
1H), 4.81 – 4.72 (m, 2H), 3.92 (t, J = 6.5 Hz, 2H), 3.58 (d, J = 11.5 Hz, 6H), 2.77 (d, J = 21.5 Hz, 
2H), 1.89 – 1.84 (m, 2H), 1.48 – 1.42 (m, 2H), 1.29 – 1.24 (m, 2H); 13C NMR (125 MHz, CDCl3) 
δ 165.4(d, J = 5.7 Hz), 137.9, 114.6(t, J = 25.6 Hz), 65.2(t, J = 19.9 Hz), 52.8(m), 33.6(t, J = 16.2 
Hz), 32.9(m), 32.5(t, J = 14.4 Hz), 27.7, 24.7(m); 31P NMR (200 MHz, CDCl3) δ 22.6; HRMS 
(ESI) m/z calcd for C10H20O5P+ [M+H]+ 251.1043, found 251.1044. IR (thin film, cm-1) 2956, 
1733, 1274. 
 
Scheme 2.9.6: Synthesis of (E)-9-hydroxynon-5-en-1-yl 2-(dimethoxyphosphoryl)acetate 
(132-2b) 
 65 
 
Hex-5-en-1-yl 2-(dimethoxyphosphoryl)acetate 132-2a (250 mg, 1 mmol), pent-4-en-1-ol 
(215 mg, 2.5 mmol) and Grubbs II catalyst (42 mg, 0.05 mmol) were added to DCM (20 mL). The 
mixture was refluxed for 24 h. Then it was loaded on column directly and purified by flash column 
chromatography (100% EtOAc) to provide compound 132-2b (215 mg, 70% yield). 1H NMR (500 
MHz, CDCl3) δ 5.42 – 5.40 (m, 2H), 4.14 (t, J = 6.5 Hz, 2H), 3.79 (d, J = 11.5 Hz, 6H), 3.63 (t, J 
= 6.5 Hz, 2H), 2.96 (d, J = 22.0 Hz, 2H), 2.12 – 1.99 (m, 4H), 1.82 (br, 1H),1.67 – 1.58 (m, 4H), 
1.44 – 1.40 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 165.6(d, J = 5.7 Hz), 130.3, 129.9, 65.6, 62.0, 
53.1(d, J = 6.7 Hz), 33.8, 32.7, 32.3, 31.9, 28.7, 27.7, 25.4; 31P NMR (200 MHz, CDCl3) δ 22.6; 
HRMS (ESI) m/z calcd for C13H26O6P+ [M+H]+ 309.1462, found 309.1469. IR (thin film, cm-1) 
3431, 2932, 1735, 1274, 1059. 
 
Scheme 2.9.7: Synthesis of (3E,7E)-oxacyclododeca-3,7-dien-2-one (133-2) 
Phosphono-alcohol 132-2b (50 mg, 0.16 mmol) was added to DCM (5 mL). To this, Dess-
Martin periodinane (80 mg, 0.18 mmol) was added. The mixture was stirred at rt for 30 min before 
it was diluted with DCM (20 mL) and 1 mL of a 1:1 mixture of saturated NaHCO3 and 2.0% 
Na2S2O3. The mixture was stirred vigorously for 5 min (until the organic phase was clear) and the 
phases were separated. The organic phase was dried over MgSO4, filtered, and concentrated in 
vacuo to yield aldehyde 132-2 which was used directly in the next step. 
Tetramethylethylenediamine (0.036 mL, 0.24 mmol) and triethylamine (0.112 mL, 0.8 
mmol) were added to a suspension of Zn(OTf)2 (203.7 mg, 0.440 mmol) in THF (80 mL) at rt. The 
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mixture was stirred for 15 min before phosphono-aldehyde 132-2 in THF (20 mL) was added drop-
wise over 1 h by syringe pump. The resulting mixture was stirred for 15 h at rt. TLC showed 
complete reaction. The reaction mixture was concentrated to 5 mL. The residue was diluted with 
ethyl acetate (100 mL) and washed with brine (20 mL). The organic phase was dried over MgSO4, 
filtered, and concentrated in vacuo to afford a clear oil that was purified by flash column 
chromatography (hexanes/EtOAc, 90/10) to afford compound 133-2 (20.2 mg, 69% for two steps). 
1H NMR (400 MHz, CDCl3) δ 6.60 – 6.54 (m, 1H), 5.78 (d, J = 16.0 Hz, 1H), 5.38 – 5.32 (m, 1H), 
5.25 – 5.22 (m, 1H), 4.17 (t, J = 6.4 Hz, 2H), 2.30 – 2.27 (m, 4H), 2.03 – 1.99 (m, 2H), 1.59 – 1.54 
(m, 4H). 13C NMR (100 MHz, CDCl3) δ 168.9, 148.7, 133.4, 130.0, 123.6, 66.3, 31.8, 30.6, 30.5, 
26.4, 25.5; HRMS (ESI) m/z calcd for C11H17O2+ [M+H]+ 181.1223, found 181.1220. IR (thin film, 
cm-1) 2930, 1719, 1646, 1453, 1239, 1142. 
 
Scheme 2.9.8: Synthesis of (Z)-4-iodobut-3-en-1-yl 2-(dimethoxyphosphoryl)acetate (132-3a) 
(Z)-4-Iodobut-3-en-1-ol59 (495 mg, 2.5 mmol) was dissolved in DCM (20 mL). 
Triethylamine (505 mg, 5.0 mmol) was added. Dimethyl (2-chloro-2-oxoethyl)phosphonate (930 
mg, 5.0 mmol) in DCM (5 mL) was added slowly. The mixture was stirred at rt. TLC analysis 
showed complete reaction after 2 hours. The mixture was washed with brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The mixture was purified by flash column chromatography 
(hexanes/EtOAc, 50/50) to provide compound 132-3a (760 mg, 88% yield). 1H NMR (400 MHz, 
CDCl3) δ 6.39 – 6.37 (m, 1H), 6.26 – 6.24 (m, 1H), 4.23 (t, J = 6.4 Hz, 2H), 3.81 (d, J = 11.2 Hz, 
6H), 2.99 (d, J = 21.2 Hz, 2H), 2.54 – 2.49 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 165.5(d, J = 
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5.7 Hz), 136.5, 85.3, 63.4, 53.2 (d, J = 5.7 Hz), 34.2, 33.9, 32.8 ; 31P NMR (200 MHz, CDCl3) δ 
22.3; HRMS (ESI) m/z calcd for C8H15IO5P+ [M+H]+ 348.9696, found 348.9704; IR (thin film, 
cm-1) 2956, 1733, 1458, 1272. 
 
Scheme 2.9.9: Synthesis of (Z)-9-hydroxynon-3-en-1-yl 2-(dimethoxyphosphoryl)acetate 
(132-3d) 
tert-Butyldimethyl(pent-4-en-1-yloxy)silane (300 mg, 1.5 mmol) was dissolved in THF (5 
mL). To this solution, 9-BBN (6.0 mL, 3.0 mmol, 0.5 M in THF) was added. The mixture was 
stirred at rt for 3 h. Then, NaOH (1.0 N, 3 mL) was added to the mixture and the reaction was 
stirred for an additional 30 min to form 132-3b in situ. 
To this, phosphate 132-3a (348 mg, 1 mmol) and Pd(dppf)Cl2·DCM (33 mg, 0.04 mmol) 
were added. This mixture was stirred for 15 h at rt before being quenched with brine and extracted 
with EtOAc. The organic layer was washed with brine, dried over MgSO4, filtered, and 
concentrated in vacuo to give 132-3c. 
The crude product 132-3c was dissolved in THF (10 mL) and TBAF (2.0 mL, 2.0 mmol, 1.0 
M in THF) was added. The mixture was stirred at rt for 3 h, then diluted with water and extracted 
with EtOAc. The combined organic layers were washed with brine, dried over MgSO4, filtered, 
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and concentrated in vacuo. The mixture was purified by flash column chromatography (100% 
EtOAc) to provide compound 132-3d (204 mg, 67% yield). 1H NMR (400 MHz, CDCl3) δ 5.51 – 
5.48 (m, 1H), 5.35 – 5.32 (m, 1H), 4.13 (t, J = 6.8 Hz, 2H), 3.80 (d, J = 11.2 Hz, 6H), 3.62 (t, J = 
6.4 Hz, 2H), 2.97 (d, J = 21.6 Hz, 2H), 2.42 – 2.37 (m, 2H), 2.06 – 2.03 (m, 2H), 1.58 – 1.53 (m, 
2H), 1.38 – 1.34 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 165.6 (d, J = 5.7 Hz), 132.9, 124.0, 65.2, 
62.7, 53.2 (d, J = 5.7 Hz), 33.9, 32.8, 32.6, 29.2, 27.2, 26.6, 25.3; 31P NMR (200 MHz, CDCl3) δ 
22.5; HRMS (ESI) m/z calcd for C13H26O6P+ [M+H]+ 309.1462, found 309.1470. IR (thin film, 
cm-1) 3433, 2931, 1737, 1269, 1032. 
 
Scheme 2.9.10: Synthesis of (3E,9Z)-oxacyclododeca-3,9-dien-2-one (133-3) 
Phosphono-alcohol 132-3d (50 mg, 0.16 mmol) was added to DCM (5 mL). To this, Dess-
Martin periodinane (80 mg, 0.18 mmol) was added. The mixture was stirred at rt for 30 min before 
it was diluted with DCM (20 mL) and 1 mL of a 1:1 mixture of saturated NaHCO3 and 2.0% 
Na2S2O3. The mixture was stirred vigorously for 5 min (until the organic phase was clear) and the 
phases were separated. The organic phase was dried over MgSO4, filtered, and concentrated in 
vacuo to yield aldehyde 132-3 which was used directly in the next step. 
Tetramethylethylenediamine (0.036 mL, 0.24 mmol) and triethylamine (0.112 mL, 0.8 
mmol) were added to a suspension of Zn(OTf)2 (203.7 mg, 0.440 mmol) in THF (80 mL) at rt. The 
mixture was stirred for 15 min before phosphono-aldehyde 132-3 in THF (20 mL) was added drop-
wise over 1 h by syringe pump. The resulting mixture was stirred for 15 h at rt. TLC showed 
complete reaction. The reaction mixture was concentrated to 5 mL. The residue was diluted with 
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ethyl acetate (100 mL) and washed with brine (20 mL). The organic phase was dried over MgSO4, 
filtered, and concentrated in vacuo to yield a clear oil that was purified by flash column 
chromatography (hexanes/EtOAc, 90/10) to afford compound 133-3 (21.5 mg, 73% for two steps). 
1H NMR (500 MHz, CDCl3) δ 7.10 – 7.04 (m, 1H), 5.80 (d, J = 16.0 Hz, 1H), 5.38 – 5.31 (m, 2H), 
4.33 – 4.30 (m, 2H), 2.28 – 2.17 (m, 4H), 2.01 – 1.97 (m, 2H), 1.65 – 1.60 (m, 2H), 1.50 – 1.49 
(m, 2H). 13C NMR (125 MHz, CDCl3) δ 168.1, 152.5, 133.0, 125.2, 122.4, 64.3, 33.1, 28.8, 27.2, 
26.9, 26.8; HRMS (ESI) m/z calcd for C11H17O2+ [M+H]+181.1223, found 181.1218. IR (thin film, 
cm-1) 2924, 1729, 1272, 1121. 
 
Scheme 2.9.11: Synthesis of (3E,15E)-1,13-dioxacyclotetracosa-3,15-diene-2,14-dione 
(133-4a) 
9-hydroxynonyl 2-(dimethoxyphosphoryl)acetate61 (50 mg, 0.16 mmol) was added to DCM 
(5 mL). To this, Dess-Martin periodinane (80 mg, 0.18 mmol) was added. The mixture was stirred 
at rt for 30 min before it was diluted with DCM (20 mL) and 1 mL of a 1:1 mixture of saturated 
NaHCO3 and 2.0% Na2S2O3. The mixture was stirred vigorously for 5 min (until the organic phase 
was clear) and the phases were separated. The organic phase was dried over MgSO4, filtered, and 
concentrated in vacuo to yield aldehyde 132-4 which was used directly. 
Tetramethylethylenediamine (0.036 mL, 0.24 mmol) and triethylamine (0.112 mL, 0.8 
mmol) were added to a suspension of Zn(OTf)2 (203.7 mg, 0.440 mmol) in THF (80 mL) at rt. The 
mixture was stirred for 15 min before phosphono-aldehyde 132-4 in THF (20 mL) was added drop-
wise over 1 h by syringe pump. The resulting mixture was stirred for 15 h at rt. TLC showed 
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complete reaction. The reaction mixture was concentrated to 5 mL. The residue was diluted with 
ethyl acetate (100 mL) and washed with brine (20 mL). The organic phase was dried over MgSO4, 
filtered, and concentrated in vacuo to yield a clear oil that was purified by flash column 
chromatography (hexanes/EtOAc, 90/10) to afford compound 133-4a (24.5 mg, 83% for two 
steps). 1H NMR (500 MHz, CDCl3) δ 6.96 – 6.93 (m, 2H), 5.83 (d, J = 16.0 Hz, 2H), 4.16 (t, J = 
6.0 Hz, 4H), 2.26 – 2.18 (m, 4H), 1.69 – 1.27 (m, 24H). 13C NMR (125 MHz, CDCl3) δ 166.8, 
149.3, 121.6, 64.3, 31.7, 28.9, 28.6, 28.5, 27.8, 27.4, 26.0; HRMS (ESI) m/z calcd for C22H37O4+ 
[M+H]+ 365.2686, found 365.2689. IR (thin film, cm-1) 2930, 1712, 1654, 1462, 1265. 
2.10 Total synthesis of lactimidomycin (procedures & analytical/spectral data) 
 
Scheme 2.10.1: Synthesis of (S)-3-((4S,5R,E)-5-((tert-butyldimethylsilyl)oxy)-2,4-
dimethylhex-2-enoyl)-4-isopropyloxaz-olidin-2-one (135a) 
Imidazole (5.29 g, 77.6 mmol) and DMAP (948 mg, 7.76 mmol) were added to a stirred 
solution of (S)-3-((4S,5R,E)-5-hydroxy-2,4-dimethylhex-2-enoyl)-4-isopropyloxazolidin-2-one62, 
63 (6.97 g, 25.9 mmol) and DCM (100 mL) at 0 °C. The resulting mixture was stirred for 15 minutes 
at this temperature before adding TBSCl (7.8 g, 51.8 mmol). The reaction was allowed to warm to 
rt and stirred for 19 h before quenching with water (150 mL) and stirring for 5 minutes. The 
aqueous phase was extracted with DCM (3 x 40 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product 135a (10.2 g) was a yellow oil 
which was advanced to the next step without purification. An analytical quantity of this product 
was purified by flash column chromatography (hexanes/EtOAc, 80/20) to assess spectral 
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information. [α]24D = +27.8 (c 5.53, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.07 – 6.02 (m, 1H), 
4.50 (ddd, J = 8.8, 5.4, 4.3 Hz, 1H), 4.29 (t, J = 8.9 Hz, 1H), 4.15 (dd, J = 8.9, 5.5 Hz, 1H), 3.79 
(qd, J = 6.2, 3.6 Hz, 1H), 2.52 (dqd, J = 10.3, 6.8, 3.5 Hz, 1H), 2.42 – 2.29 (m, 1H), 1.90 (d, J = 
1.4 Hz, 3H), 1.11 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.9 Hz, 3H), 0.90 (t, J = 6.8 Hz, 6H), 0.87 (s, 
9H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.1, 153.5, 141.3, 130.6, 71.2, 
63.3, 58.2, 40.2, 28.2, 25.8, 21.3, 18.0, 17.8, 15.9, 14.9, 13.6, -4.3, -4.9; HRMS (ESI) m/z calcd 
for C20H38NO4Si+ [M+H]+: 384.2565, found 384.2565; HRMS (ESI) m/z calcd for 
C20H37NO4SiNa+ [M+Na]+: 406.2384, found 406.2382; IR (thin film, cm-1) 2961, 2930, 2858, 
1788, 1684, 1487, 1472, 1464, 1388, 1365, 1300, 1258, 1208, 1109, 1096, 1062, 1036, 1008, 965, 
942, 880, 838, 801, 775, 756, 733, 696, 684, 666. 
 
Scheme 2.10.2: Synthesis of (4S,5R,E)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethylhex-2-en-
1-ol (135b) 
NaBH4 (4.9 g, 129.4 mmol) in water (50 mL) was added to a stirred solution of crude 
oxazolidinone 135a (9.93 g) in THF (100 mL) at 0 °C. The reaction was allowed to warm to rt and 
stirred for 12.5 h before quenching with saturated NH4Cl (100 mL) slowly. The aqueous phase was 
extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. The crude product was purified by flash column chromatography 
(hexanes/EtOAc, 80/20) to yield 135b as a clear, colorless oil (5.6 g, 84% yield across two steps). 
[α]24D = -4.7 (c 5.38, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.30 (ddd, J = 9.7, 2.4, 1.2 Hz, 1H), 
4.01 (d, J = 0.8 Hz, 2H), 3.68 (qd, J = 6.2, 4.5 Hz, 1H), 2.46 – 2.35 (m, 1H), 1.67 (d, J = 1.3 Hz, 
3H), 1.35 (s, 1H), 1.04 (d, J = 6.2 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 3H), 
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0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 134.5, 129.1, 71.8, 69.2, 39.5, 25.9, 20.8, 18.1, 16.4, 
13.9, -4.4, -4.8; HRMS (ESI) m/z calcd for C14H30O2SiNa+ [M+Na]+: 281.1907, found 281.1907; 
IR (thin film, cm-1) 3316, 2958, 2930, 2858, 1472, 1462, 1374, 1362, 1255, 1167, 1132, 1106, 
1066, 1030, 1006, 958, 940, 838, 798, 774, 666. 
 
Scheme 2.10.3: Synthesis of (4S,5R,E)-5-((tert-butyldimethylsilyl)oxy)-2,4-dimethylhex-2-
enal (135) 
DMSO (16.09 mL, 226.6 mmol) was added to a solution of alcohol 135b (3.93 g, 15.2 mmol) 
in DCM (80 mL). The resulting mixture was cooled to 0 °C. Triethylamine (10.75 mL, 77.1 mmol) 
and SO3-Pyridine (9.75 g, 61.3 mmol) were added, and the mixture was stirred for 2 h at 0 °C. 
Additional SO3-Pyridine (3.44 g, 21.61 mmol) was added, and the reaction was stirred for another 
2 h at 0 °C and then at rt for 1 h. After a total of 5 h, the reaction was diluted with EtOAc (100 
mL) and quenched with HCl (2.0 N, 50 mL). The aqueous phase was extracted with EtOAc (2 x 
25 mL). The combined organic layers were washed with saturated NaHCO3 (70 mL) and 
brine/water (1/1, 70 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product 135 (4.1 g) was a yellow oil, which was advanced to the next step without purification. 1H 
NMR (400 MHz, CDCl3) δ 9.41 (s, 1H), 6.46 (d, J = 10.0 Hz, 1H), 3.86 – 3.73 (m, 1H), 2.74 – 
2.63 (m, 1H), 1.75 (s, 3H), 1.10 (d, J = 6.2 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.05 (s, 
3H), 0.04 (s, 3H). 
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Scheme 2.10.4: Synthesis of (R)-4-benzyl-3-((2R,3R,6S,7R,E)-7-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-2,4,6-trimethyl-oct-4-enoyl)oxazolidin-2-one (137a) 
n-Bu2BOTf (17.53 mL, 17.53 mmol, 1.0 M in DCM) and triethylamine (2.97 mL, 21.3 
mmol) were added to a stirred solution of (R)-4-benzyl-3-propionyloxazolidin-2-one (3.91, 16.8 
mmol) (136) in DCM (50 mL) at -10 °C. This mixture was stirred for 1 h and was cooled to -78 °C 
before adding crude aldehyde 135 (4.1 g). The reaction was kept at -78 °C for 1 hour, warmed to 
0°C, and stirred for an additional 2 h. The reaction was quenched with MeOH/pH 7 buffer (2/1, 39 
mL) and MeOH/H2O2 (30%) (2/1, 39 mL) and stirred for 1 h at 0°C. The reaction mixture was 
concentrated in vacuo, diluted with EtOAc (100 mL) and washed with saturated NaHCO3. The 
aqueous phase was extracted with EtOAc (2 x 30 mL). The combined organic layers were washed 
with brine (75 mL), and the aqueous phase was back extracted with EtOAc (40 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. This material was 
filtered through a short column of silica (hexanes/EtOAc/Et3N, 81/18/1) to yield the crude product 
137a (7.21 g) as a clear, yellow-colored oil, which was advanced to the next step without further 
purification. 
 
Scheme 2.10.5: Synthesis of (R)-4-benzyl-3-((2R,3R,6S,7R,E)-7-((tert-
butyldimethylsilyl)oxy)-2,4,6-trimethyl-3-((trimethylsilyl)oxy)oct-4-enoyl)oxazolidin-2-one 
(137) 
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Imidazole (4.01 g, 58.9 mmol) and TMSCl (3.74 mL, 29.4 mmol) were added to a solution 
of compound 137a (7.21 g) in DCM (55 mL). This mixture was stirred for 20 h at rt, before it was 
diluted with EtOAc (100 mL). The organic phase was washed with HCl (0.2 N, 45 mL), and the 
aqueous phase was extracted with EtOAc (3 x 30 mL). The combined organic layers were washed 
with saturated NaHCO3 (50 mL) and brine (50 mL), dried over MgSO4, filtered, and concentrated 
in vacuo. The crude product was purified by flash column chromatography (hexanes/EtOAc/Et3N, 
85/14/1  79/20/1) to yield 137 as a clear, colorless oil (6.82 g, 79% yield across three steps). 
[α]24D = -21.8 (c 5.315, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.16 (m, 5H), 5.35 (d, J = 
9.8 Hz, 1H), 4.54 (dddd, J = 9.7, 7.5, 3.1, 2.2 Hz, 1H), 4.31 (d, J = 6.6 Hz, 1H), 4.15 (dd, J = 9.1, 
2.2 Hz, 1H), 4.12 – 4.04 (m, 2H), 3.69 (qd, J = 6.2, 2.8 Hz, 1H), 3.27 (dd, J = 13.3, 3.1 Hz, 1H), 
2.75 (dd, J = 13.3, 9.7 Hz, 1H), 2.42 – 2.32 (m, 1H), 1.58 (d, J = 1.2 Hz, 3H), 1.18 (d, J = 6.8 Hz, 
3H), 0.95 (d, J = 2.7 Hz, 3H), 0.94 (d, J = 2.1 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 9H), 0.03 (s, 3H), 
0.01 (s, 3H); 13C NMR (175 MHz, CDCl3) δ 174.9, 153.0, 135.4, 134.8, 129.4, 129.4, 128.9, 127.3, 
78.5, 71.4, 65.8, 55.7, 42.0, 39.1, 37.7, 25.9, 20.8, 18.1, 16.4, 12.8, 11.9, -0.1, -4.4, -4.8; HRMS 
(ESI) m/z calcd for C30H51NO5Si2Na+ [M+Na]+: 584.3198, found 584.3202; IR (thin film, cm-1) 
2958, 2930, 2858, 1784, 1702, 1472, 1455, 1377, 1362, 1291, 1251, 1209, 1195, 1106, 1073, 1030, 
967, 909, 890, 839, 799, 775, 760, 702, 668. 
 
Scheme 2.10.6: Synthesis of (2R,3R,6S,7R,E)-S-ethyl_7-((tert-butyldimethylsilyl)oxy)-2,4,6-
trimethyl-3-((trimethylsilyl)oxy)oct-4-enethioate (138a) 
n-BuLi (9.27 mL, 14.83 mmol, 1.6 M in THF) was added to a solution of ethanethiol (1.69 
mL, 22.8 mmol) in THF (60 mL) at –20 °C. In a separate flask, compound 137 (6.60 g, 11.8 mmol) 
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in THF (50 mL + 5 mL rinse) was cooled to -20 °C and then added to the reaction mixture. After 
2 h, the reaction was diluted with EtOAc (50 mL), quenched with saturated NH4Cl (75 mL), and 
warmed to rt. The aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic 
layers were washed with saturated NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The crude product was purified by a flash column 
chromatography (hexanes/EtOAc/Et3N, 82/17/1) to yield 138a as a clear, colorless oil (4.35 g, 
83% yield). [α]24D = -17.6 (c 5.18, CHCl3); 1H NMR (500 MHz, CDCl3) δ 5.23 (d, J = 9.7 Hz, 
1H), 4.13 (d, J = 8.2 Hz, 1H), 3.68 (qd, J = 6.2, 3.1 Hz, 1H), 2.88 – 2.78 (m, 2H), 2.73 (dq, J = 
13.3, 7.5 Hz, 1H), 2.42 – 2.35 (m, 1H), 1.60 (d, J = 1.3 Hz, 3H), 1.20 (t, J = 7.5 Hz, 3H), 1.17 (d, 
J = 6.8 Hz, 3H), 0.92 (dd, J = 6.5, 4.3 Hz, 6H), 0.89 (s, 9H), 0.06 (s, 9H), 0.02 (d, J = 4.5 Hz, 6H); 
13C NMR (125 MHz, CDCl3) δ 201.5, 134.6, 130.5, 80.2, 71.0, 53.1, 39.0, 25.9, 23.0, 20.0, 18.1, 
15.3, 14.5, 14.0, 11.4, 0.1, -4.4, -4.9; HRMS (ESI) m/z calcd for C22H46O3SSi2Na+ [M+Na]+: 
469.2598, found 469.2618; IR (thin film, cm-1) 2958, 2931, 2858, 1690, 1472, 1456, 1412, 1375, 
1320, 1297, 1251, 1212, 1187, 1166, 1132, 1099, 1072, 1029, 1006, 964, 907, 887, 869, 839, 799, 
774, 749, 725, 667, 642, 634, 608, 542. 
 
Scheme 2.10.7: Synthesis of (2R,3R,6S,7R,E)-7-((tert-butyldimethylsilyl)oxy)-2,4,6-
trimethyl-3-((trimethylsilyl)oxy)oct-4-enal (138) 
DIBAL-H (12.6 mL, 12.6 mmol, 1.0 M in DCM) was added via syringe pump over 10 
minutes to a stirred solution of thioester 138a (4.31 g, 9.66 mmol), in DCM (100 mL) at -78 °C. 
After 30 minutes, the reaction was quenched with MeOH (20 mL) cooled to -78 °C. The reaction 
was warmed to rt and was partially concentrated in vacuo to remove about half of the solvent. The 
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reaction mixture was diluted with EtOAc (75 mL) and Rochelle’s salt solution (75 mL), and the 
biphasic mixture was stirred for 30 minutes and then separated. The aqueous phase was extracted 
with EtOAc (3 x 30 mL), and the combined organic layers were washed with NaOH (1.0 M, 2 x 
40 mL), saturated NaHCO3 (50 mL), and brine (75 mL). The combined aqueous layers were further 
extracted with EtOAc (3 x 50 mL) and washed with brine (100 mL). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. This material was filtered through a 
short column of silica (hexanes/EtOAc, 90/10) to yield the crude product 138 (3.81 g) as a clear, 
colorless oil, which was used immediately in the next reaction. 1H NMR (500 MHz, CDCl3) δ 9.63 
(d, J = 2.2 Hz, 1H), 5.37 (d, J = 9.7 Hz, 1H), 4.26 (dd, J = 6.4, 0.5 Hz, 1H), 3.72 (qd, J = 6.2, 2.9 
Hz, 1H), 2.51 (pd, J = 6.8, 2.2 Hz, 1H), 2.42 – 2.34 (m, 1H), 1.56 (d, J = 1.3 Hz, 3H), 1.03 (d, J = 
6.8 Hz, 3H), 0.97 (d, J = 6.2 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.08 (s, 9H), 0.03 (s, 
3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 204.5, 134.5, 129.6, 77.9, 71.4, 50.6, 39.2, 25.9, 
21.1, 18.1, 16.7, 12.3, 9.2, 0.1, -4.3, -4.9; LCMS (ESI) m/z for C20H42O3Si2Na+ [M+Na]+: 409.1. 
 
Scheme 2.10.8: Synthesis of (4R,7S,8R,E)-4-((S,Z)-4-iodobut-3-en-2-yl)-2,2,5,7,8,10,10,11,11-
nonamethyl-3,9-dioxa-2,10-disiladodec-5-ene (150a) 
NaHMDS (19.38 mL, 19.38 mmol, 1.0 M in THF) was added to a stirred suspension of 
iodomethylenetriphenylphosphonium iodide in THF (50 mL). The reaction mixture was stirred for 
7 minutes, sonicated for 3 minutes, and cooled to -78 °C. Aldehyde 138 (3.81 g) was added in THF 
(5 mL, 2 x 3 mL rinse) slowly. The reaction mixture was stirred for 45 minutes at -78 °C, let warm 
to rt over 30 minutes, and quenched with saturated NH4Cl (75 mL). The biphasic mixture was 
extracted with EtOAc (3 x 50 mL), and the combined organic layers were washed with saturated 
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NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered, and concentrated in vacuo. 
The crude product was purified by flash column chromatography (hexanes/EtOAc/Et3N, 
98.5/0.5/1,) to yield 150a as a yellow colored oil (3.35 g, 68% yield across two steps). [α]24D = 
+64.5 (c 4.76, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.06 (dd, J = 7.4, 0.5 Hz, 1H), 5.85 (dd, J = 
9.2, 7.4 Hz, 1H), 5.18 (d, J = 9.7 Hz, 1H), 3.83 (d, J = 7.9 Hz, 1H), 3.71 (qd, J = 6.2, 2.8 Hz, 1H), 
2.73 – 2.59 (m, 1H), 2.43 – 2.30 (m, 1H), 1.57 (d, J = 1.3 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H), 0.96 
(d, J = 6.3 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.07 (s, 9H), 0.04 (s, 3H), 0.03 ([s, 3H); 
13C NMR (125 MHz, CDCl3) δ 144.2, 136.2, 129.1, 81.9, 80.5, 71.6, 43.8, 38.9, 25.9, 21.0, 18.1, 
16.5, 15.5, 11.9, 0.1, -4.3, -4.8; HRMS (ESI) m/z calcd for C21H43IO2Si2Na+ [M+Na]+: 533.1738, 
found 533.1742; IR (thin film, cm-1) 2957, 2928, 2857, 1472, 1461, 1406, 1374, 1312, 1279, 1250, 
1165, 1104, 1094, 1067, 1028, 1006, 962, 885, 838, 798, 774, 748, 706, 669. 
 
Scheme 2.10.9: Synthesis of (1Z,3S,4R,5E,7S,8R)-8-((tert-butyldimethylsilyl)oxy)-1-iodo-
3,5,7-trimethylnona-1,5-dien-4-ol (150b) 
p-TSA in DCM/MeOH (90/10, 2 mL) was added slowly to a stirred solution of compound 
150a (3.35 g, 6.56 mmol) in DCM/MeOH (90/10, 68 mL) at 0 °C. After 40 minutes, the reaction 
was quenched with saturated NaHCO3/water (1/1, 50 mL) and warmed to rt while stirring. The 
aqueous layer was extracted with EtOAc (3 x 30 mL), and the combined organics were dried over 
MgSO4, filtered, and concentrated in vacuo to yield the crude product 150b (2.71 g) as a yellow 
oil, which was advanced to the next step without purification. [α]24D = +74 (c 0.97, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 6.12 (d, J = 7.4 Hz, 1H), 5.94 (dd, J = 9.2, 7.4 Hz, 1H), 5.28 (d, J = 
9.6 Hz, 1H), 3.94 (dd, J = 7.7, 2.3 Hz, 1H), 3.70 (qd, J = 6.2, 3.4 Hz, 1H), 2.78 – 2.65 (m, 1H), 
 78 
 
2.38 (dqd, J = 10.1, 6.8, 3.4 Hz, 1H), 1.62 (d, J = 1.3 Hz, 3H), 1.47 (s, 1H), 1.06 (d, J = 6.7 Hz, 
3H), 0.98 (d, J = 6.2 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 143.8, 135.9, 130.1, 81.1, 80.9, 71.6, 43.1, 39.2, 25.9, 21.0, 18.1, 16.7, 
15.0, 12.2, -4.3, -4.8; HRMS (ESI) m/z calcd for C18H35IO2SiNa+ [M+Na]+: 461.1343, found 
461.1342. 
 
Scheme 2.10.10: Synthesis of (1Z,3S,5E,7S,8R)-8-((tert-butyldimethylsilyl)oxy)-1-iodo-3,5,7-
trimethylnona-1,5-dien-4-yl 2-(dimethoxyphosphoryl)acetate (150) 
DMAP (226 mg, 1.85 mmol) was added to a solution of the crude alcohol 150b (2.71 g) in 
THF (50 mL) at 0 °C. Pyridine (2.55 mL, 31.7 mmol) and acyl chloride (21.8 mL, 0.8 M in THF) 
were added slowly, the reaction was stirred at 0 °C for 5 min and then warmed to rt. After 90 
minutes, the reaction was diluted with DCM (200 mL), washed with HCl (1.0 N, 100 mL), CuSO4 
(0.1 M, 100 mL), water (2 x 100 mL), and saturated NaHCO3 (100 mL). The organic phase was 
dried over MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography (hexanes/EtOAc, 50/50) to yield 150 as a clear, yellow colored oil (1.681 
g, 44% yieldiv across 2 steps). [α]24D = +63.9 (c 1.03, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.18 
(d, J = 7.5 Hz, 1H), 5.91 (dd, J = 9.2, 7.5 Hz, 1H), 5.34 (d, J = 9.6 Hz, 1H), 5.15 (d, J = 8.5 Hz, 
1H), 3.80 (dd, J = 11.2, 1.7 Hz, 6H), 3.69 (qd, J = 6.2, 3.2 Hz, 1H), 3.00 (dd, J = 21.7, 1.7 Hz, 2H), 
 
iv This is an unoptimized yield. Executing similar procedure on a smaller scale (100 mg) using a 
0.06 M concentration of crude compound 47a in THF and adding a 0.4 M concentration of acyl 
chloride in THF provided the desired product in significantly higher yield (85% across 2 steps).  
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2.97 – 2.87 (m, 1H), 2.42 – 2.28 (m, 1H), 1.62 (s, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 6.3 
Hz, 3H), 0.94 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H); 13C NMR (175 MHz, 
CDCl3) δ 164.6 (d, J = 6.4 Hz), 142.3, 132.6, 131.2, 83.1, 82.2, 71.5, 53.0 (dd, J = 7.5, 6.6 Hz), 
41.8, 39.2, 33.9, 33.2, 25.8, 21.0, 18.0, 16.5, 15.2, 12.6, -4.4, -4.8; HRMS (ESI) m/z calcd for 
C22H42IO6PSiNa+ [M+Na]+: 611.1425, found 611.1423; IR (thin film, cm-1) 2957, 2929, 2856, 
1738, 1472, 1462, 1375, 1272, 1258, 1185, 1107, 1059, 1033, 964, 931, 837, 803, 774, 705, 668. 
  
Scheme 2.10.11: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-14-
hydroxy-3,5,7-trimethyltetra-deca-4,8,10-trien-6-yl 2-(dimethoxyphosphoryl)acetate (148) 
Cis-iodide 150 (907 mg, 1.54 mmol) and boronic acid 1513 (493 mg, 3.85 mmol) were added 
to THF/H2O (3:1, 12.5 mL) and stirred until they dissolved. NaOH (1.0 M, 3.1 mL) was added to 
the solution, which was then stirred for 2 minutes. Next, Pd(dppf)Cl2·DCM (63 mg, 0.077 mmol) 
in THF/H2O (1 mL + 0.5 mL wash) was added. The reaction mixture was stirred for 18 h and 
quenched with pH 7 buffer (30 mL). The aqueous phase was extracted with EtOAc (3 x 35 mL), 
and the combined organic layers were washed with brine (2 x 50 mL), back extracted with EtOAc 
(20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified 
by flash column chromatography (100% EtOAc) to yield 148 as a yellow oil (711 mg, 84% yield). 
[α]24D = +56.8 (c 3.595, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.34 – 6.22 (m, 1H), 5.89 (t, J = 
11.0 Hz, 1H), 5.74 – 5.62 (m, 1H), 5.33 (d, J = 9.7 Hz, 1H), 5.06 – 4.93 (m, 2H), 3.80 (dd, J = 
11.2, 4.4 Hz, 6H), 3.66 (dd, J = 7.8, 5.2 Hz, 3H), 3.07 – 2.90 (m, 3H), 2.38 – 2.26 (m, 1H), 2.19 
(q, J = 7.2 Hz, 2H), 1.71 – 1.64 (m, 2H), 1.56 (d, J = 1.2 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.94 
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(d, J = 6.2 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 2.7 Hz, 9H), 0.01 (s, 6H); 13C NMR (175 
MHz, CDCl3) δ 164.7 (d, J = 6.2 Hz), 134.7, 132.7, 131.4, 130.6, 128.5, 125.7, 84.9, 71.4, 62.1, 
53.0 (dd, J = 6.5, 5.2 Hz), 39.1, 34.6, 33.9, 33.1, 32.1, 29.1, 25.8, 20.6, 18.0, 17.4, 16.2, 12.2, -4.5, 
-4.9; HRMS (ESI) m/z calcd for C27H51O7PSiNa+ [M+Na]+: 569.3034, found 569.3039; IR (thin 
film, cm-1) 3440, 2957, 2930, 2857, 1736, 1472, 1462, 1375, 1270, 1257, 1215, 1185, 1106, 1060, 
1035, 982, 964, 928, 877, 837, 805, 774, 667. 
 
Scheme 2.10.12: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-3,5,7-
trimethyl-14-oxotetradeca-4,8,10-trien-6-yl 2-(dimethoxyphosphoryl)acetate (149) 
NaHCO3 (109.2 mg, 1.30 mmol) and DMP (882.4 mg, 2.08 mmol) were added to a solution 
of phosphono-alcohol 148 (710.9 mg, 1.30 mmol) in DCM (37 mL). This reaction mixture was 
stirred for 2 h 45 min, quenched with saturated NaHCO3 (30 mL) and Na2S2O3 (0.5 M, 30 mL), 
and then stirred for an additional 10 minutes. The aqueous layer was extracted with DCM (3 x 30 
mL) and the combined organic layers were washed with brine (50 mL). The aqueous brine wash 
was extracted again with DCM (15 mL), and the organic phase was washed with brine (15 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. This 
material was filtered through a short column of silica gel (hexanes/EtOAc, 92/8) to yield 149 as a 
yellow oil, which was used immediately in the next reaction (591.6 mg, 84% yield). 1H NMR (500 
MHz, CDCl3) δ 9.76 (t, J = 1.4 Hz, 1H), 6.33 – 6.24 (m, 1H), 5.85 (t, J = 11.0 Hz, 1H), 5.69 – 5.56 
(m, 1H), 5.32 (d, J = 9.6 Hz, 1H), 5.04 (t, J = 10.6 Hz, 1H), 4.97 (d, J = 9.0 Hz, 1H), 3.78 (dd, J = 
11.2, 2.9 Hz, 6H), 3.63 (qd, J = 6.2, 3.3 Hz, 1H), 2.97 (dd, J = 21.7, 0.7 Hz, 3H), 2.53 (t, J = 7.0 
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Hz, 2H), 2.42 (q, J = 7.1 Hz, 2H), 2.37 – 2.23 (m, 1H), 1.54 (d, J = 1.2 Hz, 3H), 1.00 (d, J = 6.6 
Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.00 (s, 6H); 13C NMR 
(125 MHz, CDCl3) δ 201.6, 164.7 (d, J = 6.4 Hz), 132.8, 132.6, 131.5, 131.4, 128.0, 126.4, 84.8, 
71.4, 53.0 (dd, J = 6.5, 2.4 Hz), 43.2, 39.1, 34.7, 34.1, 33.0, 25.8, 25.3, 20.7, 18.0, 17.4, 16.3, 12.2, 
-4.5, -4.9. 
 
Scheme 2.10.13: Synthesis of (3E,7E,9Z,11S,12R)-12-((4S,5R,E)-5-((tert-
butyldimethylsilyl)oxy)-4-methylhex-2-en-2-yl)-11-methyloxacyclododeca-3,7,9-trien-2-one 
(102) 
TMEDA (0.194 mL, 1.30 mmol) and Et3N (0.606 mL, 4.34 mmol) were added to a solution 
of Zn(OTf)2 (871 mg, 2.40 mmol) in THF (610 mL). This whitish-clear suspension was stirred for 
30 minutes, and phosphono-aldehyde 149 (591.6 mg) dissolved in THF (40 mL) was added via 
syringe pump over 30 minutes. The reaction mixture was stirred for a total of 18 h and concentrated 
in vacuo to remove the majority of the solvent. The remaining crude oil was dissolved in EtOAc 
(125 mL), washed with brine (150 mL) and back extracted with EtOAc (2 x 30 mL), washed with 
1% HCl (100 mL) and back extracted with EtOAc (30 mL), and finally washed with saturated 
NaHCO3 (100mL) and brine (150 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude product was purified by flash column 
chromatography (hexanes/EtOAc/Et3N, 96/3/1  91/8/1) to yield 102 as a clear oil product, which 
solidified under vacuum into a white crystalline solid (423 mg, 93% yield). [α]24D = -146.4 (c 1.28, 
CHCl3); [α]24D = -159.1 (c 2.46, benzene); 1H NMR (500 MHz, CDCl3) δ 6.48 (ddd, J = 15.9, 10.3, 
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5.3 Hz, 1H), 6.03 (t, J = 10.8 Hz, 1H), 5.76 (dd, J = 15.6, 10.7 Hz, 1H), 5.56 (d, J = 16.1 Hz, 1H), 
5.47 – 5.37 (m, 2H), 5.34 (d, J = 4.8 Hz, 1H), 5.13 (t, J = 11.0 Hz, 1H), 3.76 (qd, J = 6.2, 3.1 Hz, 
1H), 3.15 – 3.02 (m, 1H), 2.61 – 2.48 (m, 2H), 2.47 – 2.39 (m, 1H), 2.05 – 1.80 (m, 2H), 1.68 (d, 
J = 1.3 Hz, 3H), 1.06 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.89 
(s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 166.8, 146.3, 134.6, 133.5, 
132.3, 129.5, 128.6, 128.4, 127.5, 83.7, 71.6, 39.4, 35.9, 32.3, 31.2, 25.8, 21.3, 18.0, 17.5, 16.8, 
14.6, -4.3, -4.8; HRMS (ESI) m/z calcd for C25H42O3SiNa+ [M+Na]+: 441.2795, found 441.2807; 
IR (thin film, cm-1) 2959, 2929, 2858, 1724, 1644, 1472, 1462, 1454, 1375, 1337, 1328, 1314, 
1287, 1273, 1253, 1189, 1154, 1140, 1100, 1086, 1064, 1034, 1005, 958, 940, 837, 803, 791, 775, 
679, 666. 
 
Scheme 2.10.14: Synthesis of (3E,7E,9Z,11S,12R)-12-((4S,5R,E)-5-hydroxy-4-methylhex-2-
en-2-yl)-11-methyloxacyclodo-deca-3,7,9-trien-2-one (49) 
To a plastic Falcon Tube equipped with a septum, macrolactone 102 (40 mg, 0.096 mmol) 
and THF (2.73 mL) were added, stirred and cooled to 0 °C. HF-Pyridine complex (0.55 mL, 70% 
w/w) was added dropwise, and the reaction mixture was stirred 2 h at 0 °C and for 1 h 45 min at 
rt. Once the reaction was deemed complete by TLC, the reaction was cooled to 0 °C and slowly 
quenched by the dropwise addition of saturated NaHCO3 (30 mL) over 10 minutes. The resulting 
solution was diluted with EtOAc (20 mL), and the resulting biphasic mixture was separated. The 
aqueous layer was extracted with EtOAc (2 x 20 mL), and the combined organic layers were 
washed with CuSO4 (0.1 M, 15 mL) and water (15 mL). The organic phase was then dried over 
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MgSO4, filtered, and concentrated in vacuo to yield a crude yellow oil. The crude product was 
purified by flash column chromatography (hexanes/EtOAc, 80/20) to yield 49 as a clear, colorless 
oil (26.3 mg, 90% yield). [α]24D = -234.4 (c 1.16, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.47 
(ddd, J = 15.9, 10.3, 5.2 Hz, 1H), 6.03 (dd, J = 10.8, 10.8 Hz, 1H), 5.73 (dd, J = 15.6, 10.7 Hz, 
1H), 5.55 (d, J = 16.1 Hz, 1H), 5.40 (ddd, J = 15.2, 8.7, 6.1 Hz, 1H), 5.34 (d, J = 4.4 Hz, 1H, 
overlap), 5.33 (d, J = 8.9 Hz, 1H, overlap), 5.10 (dd, J = 10.9, 10.9 Hz, 1H), 3.60 (qd, J = 6.2, 6.2 
Hz 1H), 3.16 – 3.02 (m, 1H), 2.62 – 2.48 (m, 2H), 2.48 – 2.35 (m, 1H), 2.03 – 1.82 (m, 2H), 1.72 
(d, J = 1.2 Hz, 3H), 1.56 (br s, 1H), 1.18 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.93 (d, J = 
6.8 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 166.7, 146.4, 134.5, 133.1, 132.0, 131.7, 128.9, 128.3, 
127.7, 83.3, 71.5, 40.1, 35.6, 32.3, 31.2, 20.3, 17.5, 16.4, 15.0; HRMS (ESI) m/z calcd for 
C19H28O3Na+ [M+Na]+: 327.1931, found 327.1930; IR (thin film, cm-1) 3448, 2965, 2928, 2873, 
1717, 1642, 1452, 1375, 1337, 1328, 1314, 1273, 1190, 1142, 1086, 1002, 957, 927, 848, 830, 801, 
735, 679. 
 
Scheme 2.10.15: Synthesis of (3E,7E,9Z,11S,12R)-11-methyl-12-((S,E)-4-methyl-5-oxohex-2-
en-2-yl)oxacyclododeca-3,7,9-trien-2-one (33) 
A suspension of Dess-Martin periodinane (66.7 mg, 0.16 mmol) and NaHCO3 (8.3 mg, 0.098 
mmol) in DCM (1.0 mL + 3 x 0.5 mL rinse) was added to a solution of alcohol 49 (26 mg, 0.085 
mmol) in DCM (2 mL) at 0 °C. The mixture was stirred at 0 °C for 5 min and stirred at rt for 1 h 
30 min before the sample was concentrated in vacuo. The residue was purified by flash column 
chromatography (hexanes/EtOAc, 87/13) to yield 33 as a clear, colorless oil (19.6 mg, 75%).10 
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[α]24D = -26.2 (c 1.07, CHCl3); 1H NMR (700 MHz, CDCl3) δ 6.48 (ddd, J = 15.9, 10.3, 5.3 Hz, 
1H), 6.04 (dd, J = 10.8, 10.8 Hz, 1H), 5.73 (dd, J = 15.6, 10.6 Hz, 1H), 5.55 (d, J = 16.1 Hz, 1H), 
6.48 (ddd, J = 15.9, 10.3, 5.3 Hz, 1H), 5.38 – 5.33 (m, 2H, overlap), 5.08 (dd, J = 10.9, 10.9 Hz, 
1H), 3.43 (dq, J = 9.5, 6.8 Hz, 1H), 3.14 – 3.06 (m, 1H), 2.59-2.48 (m, 2H), 2.13 (s, 3H), 2.00 – 
1.87 (m, 2H), 1.78 (d, J = 1.2 Hz, 3H), 1.17 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C NMR 
(175 MHz, CDCl3) δ 209.1, 166.5, 146.6, 134.5, 133.3, 131.5, 129.8, 129.1, 128.2, 127.8, 82.6, 
46.9, 36.0, 32.2, 31.2, 28.0, 17.4, 16.2, 14.9; HRMS (ESI) m/z calcd for C19H26O3Na+ [M+Na]+: 
325.1774, found 325.1775; IR (thin film, cm-1) 2966, 2931, 2873, 1718, 1643, 1453, 1373, 1353, 
1337, 1314, 1243, 1189, 1141, 1089, 1002, 958, 873, 848, 829, 800, 766, 733, 719. 
 
Scheme 2.10.16: Synthesis of lactimidomycin (6)6 
Me3SiCl (29.2 μL, 0.23 mmol) and triethylamine (32.1 μL, 0.23 mmol) were added to a 
solution of ketone 33 (6.9 mg, 0.023 mmol) in THF (0.82 mL) at –78 °C. Next, LiHMDS (92 μL, 
0.092 mmol, 1.0 M in THF) was slowly introduced and the resulting mixture was stirred at –78 °C 
for 1 h. The reaction was then quenched with pH 7 phosphate buffer and extracted with DCM (3 x 
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1 mL). The combined organic phases were dried over MgSO4, filtered, and concentrated in vacuo 
to give the corresponding silyl enol ether 19, which was used in the next step without further 
purification. 
Molecular sieves (4Å, ca. 82 mg) and aldehyde 19 (4.6 mg, 0.030 mmol)64 were added to a 
solution of the crude silyl enol ether 15 in propionitrile (0.41 mL). The mixture was cooled to –78 
°C before a solution of compound 50 [prepared upon stirring of a solution of PhBCl2 (3.0 μL, 
0.023 mmol) and N-tosyl-D-tryptophan (8.1 mg, 0.023 mmol) in DCM (0.20 mL) for 1 h, followed 
by removal of the solvent]65 in propionitrile (0.12 mL) was added dropwise. After stirring for 22 
h at –78°C, the reaction was quenched with saturated NaHCO3 (1 mL). The aqueous phase was 
extracted with DCM (3 x 3 mL), and the combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo to give the crude product 6a. 
This resulting compound 6a was dissolved in THF (4 mL) at 0 °C and treated with 0.41 mL 
of a stock solution of buffered HF-pyridine [prepared from THF (3.63 mL), pyridine (1.35 mL) 
and HF-pyridine complex (0.27 mL, 70% w/w)]. The mixture was stirred at 0 °C for 2 h and at rt 
30 min to complete the desilylation. The reaction was diluted with DCM (30 mL), and the organic 
layer was washed with saturated NaHCO3 (10 mL) and CuSO4 solution (0.1 M, 3 x 15 mL), dried 
over MgSO4, filtered and concentrated in vacuo to leave a thin oil residue. This crude product was 
purified by flash column chromatography through a pipette (hexanes/EtOAc, 20/80) to give 
product 6 as a white solid (6.6 mg, 63%). [α]24D = -29.6 (c 0.66, CHCl3); [α]24D = -20.1 (c 0.25, 
DMSO); 1H NMR (700 MHz, CDCl3) δ 7.81 (br s, 1H), 6.49 (ddd, J = 15.9, 10.3, 5.3 Hz, 1H), 
6.06 (dd, J = 10.8, 10.8 Hz, 1H), 5.73 (dd, J = 15.6, 10.6 Hz, 1H), 5.55 (d, J = 16.1 Hz, 1H), 5.42 
(ddd, J = 15.3, 8.9, 6.1 Hz, 1H), 5.37 – 5.32 (m, 2H, overlap), 5.06 (dd, J = 10.9, 10.9 Hz, 1H), 
4.15-4.08 (m, 1H), 3.43 (dq, J = 9.6, 6.8 Hz, 1H), 3.22 (d, J = 1.9 Hz, 1H), 3.14 – 3.08 (m, 1H), 
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2.83 – 2.72 (m, 2H), 2.60 – 2.55 (m, 3H), 2.55 – 2.47 (m, 2H), 2.37 – 2.29 (m, 2H), 2.02 – 1.86 
(m, 2H), 1.78 (d, J = 1.2 Hz, 3H), 1.61 (ddd, J = 14.2, 10.6, 5.0 Hz, 1H), 1.32 (ddd, J = 24.9, 14.0, 
10.3 Hz, 1H), 1.19 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C NMR (175 MHz, CDCl3) δ 
212.5, 172.1, 172.0, 166.7, 147.1, 134.7, 134.2, 131.3, 129.6, 129.1, 128.3, 128.2, 82.5, 65.0, 47.6, 
46.8, 40.9, 38.6, 37.3, 36.1, 32.5, 31.4, 27.3, 17.7, 16.3, 15.5; HRMS (ESI) m/z calcd for 
C26H35NO6Na+ [M+Na]+: 480.2357, found 480.2362; IR (thin film, cm-1) 3480, 3226, 2961, 2926, 
2856, 1704, 1453, 1376, 1261, 1190, 1142, 1087, 1006, 830, 797, 766, 736, 702. 
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2.11 Lactimidomycin (6) (natural vs. synthetic NMR spectral data) 
Table 2.11.1: Comparison of the recorded 1H NMR spectral data (CDCl3) of lactimidomycin 
(6) with reported literature spectral data54 
 
Position Literature (500 MHz) Experimental (700 MHz) Δδ 
 δ (in ppm) mult. (J in Hz) δ (in ppm) mult. (J in Hz)   
2 5.53 d (16.0) 5.55 d (16.1) +0.02 
3 6.49 ddd (16.0, 10.0, 5.0) 6.49 ddd (15.9, 10.3, 5.3) 0 
4 1.96 m/2.56 m 1.94 m/2.56 m -0.02/0 
5 1.96 m/2.54 m 1.94 m/2.53 m -0.02/-0.01 
6 5.42 m 5.42 m 0 
7 5.72 dd (15.5, 10.5) 5.73 dd (15.6, 10.6) +0.01 
8 6.06 t (11.0) 6.06 t (10.8) 0 
9 5.06 t (11.0) 5.06 t (10.9) 0 
10 3.11 m 3.11 m 0 
11 5.34 m 5.34 m 0 
13 5.34 m 5.34 m 0 
14 3.44 m 3.43 m -0.01 
16 2.59 m 2.58 m -0.01 
17 4.12 m 4.12 m 0 
18 1.33 ddd (14.0, 9.0, 3.0) 1.32 ddd (13.9, 8.9, 2.9) -0.01 
  1.60 ddd (14.0, 10.5, 4.5) 1.61 (14.2, 10.6, 5.0) +0.01 
19 2.48 m 2.50 m +0.02 
20 2.34 m/2.76 m 2.33 m/2.77 m -0.01/0 
22 0.92 d (6.5) 0.92 d (6.8) 0 
23 1.78 d (1.5) 1.78 d (1.2) 0 
24 1.19 d (7.0) 1.19 d (6.8) 0 
25 2.32 m/2.80 m 2.33 m/2.79 m +0.01/-0.01 
NH 7.98 br s 7.81 br s -0.17 
OH N/A 3.22 d (1.9) N/A 
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Table 2.11.2: Comparison of the recorded 13C NMR spectral data (CDCl3) of lactimidomycin 
(6) with reported literature spectral data54 
 
Position Literature (125 MHz) Experimental (175 MHz) Δδ 
1 166.7 166.7 0 
2 128.4 128.3 -0.1 
3 147.0 147.1 +0.1 
4 32.4 32.5 +0.1 
5 31.4 31.4 0 
6 128.2 128.2 0 
7 134.6 134.7 +0.1 
8 129.6 129.6 0 
9 131.1 131.3 +0.2 
10 36.1 36.1 0 
11 82.5 82.5 0 
12 134.1 134.2 +0.1 
13 129.1 129.1 0 
14 46.8 46.8 0 
15 212.5 212.5 0 
16 47.6 47.6 0 
17 64.9 65.0 +0.1 
18 40.9 40.9 0 
19 27.3 27.3 0 
20 38.6 38.6 0 
21 172.2 172.1 -0.1 
22 17.7 17.7 0 
23 15.4 15.5 +0.1 
24 16.3 16.3 0 
25 37.3 37.3 0 
26 172.1 172.0 -0.1 
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2.12 Lactimidomycin (6) (comparison of circular dichroism [CD] spectral data) 
Figure 2.12.1: CD as reported by Ben Shen et. al. 
 
Figure 2.12.2: CD as reported by Nagorny et. al. 
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2.13 DMB side-route (procedures & analytical/spectral data) 
 
Scheme 2.13.1: Synthesis of (E)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pent-4-en-1-
ol (146a)66 
A solution of the Grubb’s II catalyst (98.6 mg, 0.116 mmol) in DCM (11.6 mL) were added 
to a flame-dried rbf equipped with reflux condenser and kept under N2 pressure. Next, 4-penten-
1-ol (200 mg, 2.32 mmol, 0.24 mL) and vinylboronic acid pinacol ester (715 mg, 4.64 mmol, 0.78 
mL) were each added via syringe, and the resulting mixture was stirred and refluxed at 45 °C for 
20 h. The reaction was allowed to cool to rt and was concentrated in vacuo to remove the majority 
of the DCM. The crude brown sludge-like mixture was purified via flash column chromatography 
(hexanes/EtOAc, 2/1) to yield the pure, viscous, brown-colored oil product 146a (410.9 mg, 83% 
yield). 1H NMR (500 MHz, CDCl3) δ 6.61 (dt, J = 17.8, 6.4 Hz, 1H), 5.44 (dd, J = 17.9, 1.6 Hz, 
1H), 3.62 (t, J = 6.5 Hz, 2H), 2.27 – 2.15 (m, 2H), 1.76 – 1.70 (br s, 1H), 1.71 – 1.63 (m, 2H), 1.24 
(s, 12H); 13C NMR (125 MHz, CDCl3) δ 153.57, 83.02, 62.22, 31.94, 31.06, 24.70;v IR (thin film, 
cm-1) 2977, 2935, 2857, 1723, 1684, 1639, 1609, 1594, 1517, 1465, 1420, 1398, 1322, 1267, 1238, 
1144, 1102, 1031, 1000, 971, 849, 807, 766, 744, 678, 641. 
 
v Typical to not see 13CNMR signal of carbon atom next to boron atom, as it is split by the 11B and 
10B isotopes into an unobservable, flattened multiplet. 
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Scheme 2.13.2: Synthesis of (E)-2-(5-((3,4-dimethoxybenzyl)oxy)pent-1-en-1-yl)-4,4,5,5-
tetramethyl-1,3,2-dioxaborolane) (146b) 
To a 15 mL RBF was added 146a (270 mg, 1.27 mmol) dissolved in THF/DMF (1:2, 4 mL) 
and TBAI was added (46.8 mg, 0.127 mmol). The reaction mixture was stirred and cooled to 0 °C. 
After 5 min, NaH (101.4 mg [60% w/w in mineral oil], 2.54 mmol) was added to this stirred 
mixture rapidly, put back under N2, and stirred at 0 °C for another 10 min, and then let warm to 0 
°C. Next, DMB-Br (587 mg, 2.54 mmol) dissolved in THF/DMF (1:2, 3 mL) was added via 
syringe, and the reaction was stirred for another 10 min at 0 °C and let warm to rt. After stirring at 
rt for 20 h, the reaction mixture was diluted with EtOAc (15 mL), washed with brine/water mixture 
(15 mL, 1:1), and extracted with EtOAc (3 x 25 mL). The combined organic fractions were washed 
with brine and dried over MgSO4, filtered, and concentrated in vacuo to yield the crude product. 
This was purified by flash column chromatography (hexanes/EtOAc, 4/1) to yield the product 
146b (180 mg, 39% yield). 1H NMR (401 MHz, CDCl3) δ 6.90 – 6.79 (m, 3H), 6.62 (dt, J = 17.9, 
6.4 Hz, 1H), 5.44 (dt, J = 18.0, 1.6 Hz, 1H), 4.41 (s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.45 (t, J = 6.6 
Hz, 2H), 2.27 – 2.17 (m, 2H), 1.79 – 1.66 (m, 2H), 1.25 (s, 12H); 13C NMR (100 MHz, CDCl3) δ 
153.64, 148.93, 148.43, 131.08, 120.10, 110.90, 110.82, 82.98, 72.73, 69.47, 55.86, 55.76, 32.30, 
28.19, 24.72;vi LRMS (ESI) m/z calcd for C20H31BO5+ [M+Na]+: 385.2, found 385.1; IR (thin film, 
cm-1) 2977, 2935, 2857, 2282, 2000, 1723, 1684, 1639, 1609, 1594, 1517, 1465, 1420, 1398, 1363, 
 
vi Typical to not see 13CNMR signal of carbon atom next to boron atom, as it is split by the 11B and 
10B isotopes into an unobservable, flattened multiplet. 
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1267, 1144, 1102, 1031, 1000, 971, 925, 901, 849, 807, 766, 679, 642, 578, 520, 440, 434, 428, 
422, 410. 
 
Scheme 2.13.3: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-14-
((3,4-dimethoxybenzyl)oxy)-3,5,7-trimethyltetradeca-4,8,10-trien-6-ol (147) 
Preparation of crude 146:vii To a 10 mL RBF was added DMB-protected 146b (85 mg, 0.234 mmol) 
in acetone/H2O (5 mL, 2:1), NaIO4 (156 mg, 0.727 mmol), NH4OAc (54.3 mg, 0.704 mmol).67 
The resulting white-colored suspension was stirred at rt for 42 h. The reaction mixture was 
concentrated in vacuo to remove most of the organic solvents, and from this crude liquid was 
 
vii 301.3 mg scale: To a RBF was added DMB-protected 146b (301.3 mg) in acetone/water (9 mL, 
2/1), NaIO4 (552 mg, 2.58 mmol), NH4OAc (192 mg, 2.50 mmol). The resulting white-colored 
suspension was stirred at rt for 46 h, 15 min. The reaction mixture was concentrated in vacuo to 
remove most of the organic solvents, and from this crude liquid was extracted with EtOAc (3 x 20 
mL). The combined organic fractions were rinsed with brine (50 mL), dried over MgSO4 for 20 
min, filtered, and concentrated in vacuo to yield the crude product. The final product (146) was 
frozen in benzene and was utilized without further purification in subsequent reactions. 
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extracted with EtOAc (3 x 20 mL). The combined organic fractions were rinsed with brine (50 
mL), dried over MgSO4, filtered, and concentrated in vacuo to yield the crude product 146. This 
crude product was frozen in benzene to store and was used directly in the subsequent Suzuki cross-
coupling reaction without further purification or characterization. 
Step 1 – Suzuki cross coupling:viii To a 5 mL RBF (oven dried) was added the vinyl iodide 145 
(56.4 mg) and boronic acid 146 (43 mg, crude), and the container was put under argon gas. Next, 
THF/H2O (0.7 mL, 3/1, pre-degassed under Ar) was added to the RBF under argon. Next, thallium 
ethoxideix (2.6 µL, 0.026 mmol) was added, followed by Pd(PPh3)4 (12.7 mg, 0.11 mmol) 
dissolvedx in degassed THF/H2O (3:1, 1.25 mL). The reaction mixture was stirred for 3 h and 
formed a solid yellow precipitate in solution. After 3 hours, the reaction appeared incomplete by 
TLC, so an addition portion of thallium ethoxide (5 µL, 0.071 mmol) and Pd(Ph3)4 (7 mg, 6.1 
µmol) was added, and a small amount of THF/H2O was carefully added to replace partially 
evaporated solvent, and the reaction was left to stir overnight. During the course of the reaction it 
 
viii 270 mg scale: The boronic acid 146 (207.3 mg, semi-crude) and vinyl iodide 145 (269.8 mg, 
0.53 mmol mmol) were dissolved in THF/H2O (3.70 mL, 3/1). The solution was degassed (freeze-
pump-thaw, three cycles), replacing the nitrogen atmosphere with an argon one. Pd(PPh3)4 (97.7 
mg, 0.0846 mmol) was added quickly, and the solution stirred for 3 min under positive Argon 
pressure. Next, thallium ethoxideix (18.0 µL, 0.254 mmol) was added quickly. A dark yellow 
precipitate formed immediately, and the solution was stirred overnight. The reaction mixture was 
quenched with pH 7 phosphate buffer and diluted with EtOAc. The heterogeneous mixture was 
stirred for 5 min and filtered through celite to remove the thallium salts, and the aqueous and 
organic phases were seperated. The aqueous fraction was reextracted with EtOAc, and the 
combined organic fractions were washed with brine, dried over MgSO4, and conc. in vacuo to 
yield an orange-colored, viscous oil crude product 147a (468 mg, crude), which was used directly 
in the larger scale deprotection reaction (footnote xi) without further purification or 
characterization. 
ix CAUTION: Thallium is highly toxic! Handle with extreme care. 
x Sonicated under Argon gas prior to addition via syringe. 
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turned from yellow to orange to brownish/blackish in color. The reaction was quenched with 3 
pipettes full of pH 7 buffer and the result mixture was transferred to a 125 mL separatory funnel. 
The round bottom flash was washed with EtOAc (3 x 15 mL) and pH 7 buffer (20) and all 
combined fractions were transferred to a separatory funnel. The organic layer was extracted, and 
the aqueous phase was back extracted with EtOAc (15 mL). The combined organic fractions were 
washed with brine (50 mL), dried over MgSO4, filtered, and concentrated in vacuo to yield an 
orange-colored, viscous oil crude product (147a) which was used directly in the subsequent 
deprotection reaction without further purification or characterization. 
Step 2 – Deprotection of TMS:xi To a 5 mL RBF was added 147a (92.1 mg, crude) in DCM/MeOH 
(90:10, 1.45 mL). This solution was put under N2, cooled to 0 °C in an ice bath, and stirred. Next, 
PTSA (0.273 mL) was quickly added via syringe. After stirring for 5 min, the reaction was checked 
by TLC and deemed incomplete. Let continue to stir for 45 min, at which point most of the SM 
had converted to product by TLC, so the reaction was quenched with NaHCO3(sat):H2O (1:1, 5 
mL), let stir for 30 min, and transferred to a separatory funnel. The mixture was extracted with 
EtOAc (3 x 7 mL), and the combined organic phases were dried over MgSO4, filtered, and 
 
xi 468 mg scale: To a 25 mL RBF was added TMS-protected 147a (468 mg, crude) in DCM/MeOH 
(90:10, 7.56 mL). This solution was put under N2, cooled to 0 °C in an ice bath, and stirred. Next, 
PTSA (1.44 mg, 7.56 μmol) dissolved in DCM/MeOH (9:1, 0.144 mL) was quickly added via 
syringe. After stirring for 3 hours at 0 °C, the reaction was quenched with sat. NaHCO3:H2O (1:1, 
50 mL), was stirred for 30 min, and was frozen in the freezer to work up the next day. After 
thawing, the organic phases were extracted using EtOAc (2 x 20 mL), combined, dried over 
MgSO4, filtered, and conc. in vacuo to yield the crude product. This product was purified via flash 
column chromatography (hexanes/EtOAc, 5/1) to obtain the pure product 147 (240 mg) as well as 
recovering unreacted starting material 147a and mixed fractions. This unreacted material 147a and 
mixed fractions were resubjected to reaction conditions following the same general procedure, 
using PTSA (0.63 mg, 3.31 μmol) and DCM:MeOH (9:1, 3.3 mL). After running for 12 hours, the 
reaction was quenched same as before, followed by extraction with EtOAc (3 x 20 mL). After 
flash column chromatography (hexanes/EtOAc, 5/1), additional pure product 147 (31.1 mg) was 
obtained, raising the total amount of the of pure product 147 (271.1 mg, 67% yield over 2 steps) 
obtained. 
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concentrated in vacuo to yield the crude product. This product was purified via flash column 
chromatography (hexanes/EtOAc, 4/1) to obtain the pure product 147 (55.1 mg, 91% yield across 
2 steps from intermediate 145). [α]24D = +61.8 (c 3.14, CHCl3); 1H NMR (500 MHz, CDCl3) δ 
6.93 – 6.79 (m, 3H), 6.36 – 6.24 (m, 1H), 5.86 (t, J = 11.0 Hz, 1H), 5.65 (dt, J = 14.5, 6.9 Hz, 1H), 
5.29 – 5.21 (m, 1H), 5.06 (t, J = 10.6 Hz, 1H), 4.43 (s, 2H), 3.89 (s, 3H), 3.88 (s, 3H), 3.78 (dd, J 
= 7.9, 3.6 Hz, 1H), 3.67 (qd, J = 6.2, 3.4 Hz, 1H), 3.46 (t, J = 6.5 Hz, 2H), 2.83 – 2.74 (m, 1H), 
2.35 (dqd, J = 10.1, 6.8, 3.4 Hz, 1H), 2.19 (q, J = 7.1 Hz, 2H), 1.76 – 1.66 (m, 2H), 1.55 (d, J = 
1.3 Hz, 3H), 1.47 (d, J = 3.7 Hz, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 6.2 Hz, 3H), 0.94 (d, J 
= 6.8 Hz, 3H), 0.88 (s, 9H), 0.02 (s, 6H); 13C NMR (126 MHz, CDCl3) δ 148.95, 148.47, 136.01, 
134.30, 132.34, 131.08, 130.28, 127.82, 125.90, 120.15, 110.92, 110.82, 82.43, 77.00, 72.84, 
71.54, 69.56, 55.90, 55.80, 39.10, 36.19, 29.47, 29.39, 25.85, 20.68, 18.06, 17.38, 16.41, 11.81, -
4.39, -4.83; HRMS (ESI) m/z calcd for C32H54O5SiNa+ [M+Na]+: 569.3638, found 569.3633; IR 
(thin film, cm-1) 2956.0, 2929.2, 2856.3, 1593.9, 1516.6, 1463.2, 1373.5, 1257.5, 1157.8, 1137.9, 
1096.5, 1030.4, 960.0, 836.5, 774.0, 429.7, 414.8, 407.9. 
 
Scheme 2.13.4: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-14-
((3,4-dimethoxybenzyl)oxy)-3,5,7-trimethyltetradeca-4,8,10-trien-6-yl 2-
(dimethoxyphosphoryl)acetate (148a) 
To a solution of alcohol 147 (164.4 mg, 0.301 mmol), THF (1.5 mL), and DMAP (11 mg). 
This reaction mixture was put under N2, cooled to 0 °C, and stirred. Pyridine (0.125 mL, 1.541 
mmol,) and dimethyl (2-chloro-2-oxoethyl)phosphonate (3 mL, 0.4 M in THF) were both slowly 
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added, in sequence, and the reaction mixture was allowed to stir for 15 min at 0 °C, let warm to rt 
and let stir overnight. The reaction mixture was concentrated in vacuo, dissolved in DCM, and 
washed with HCl (1.0 N), CuSO4 (0.1 M), and H2O (D.I.), sequentially. After each wash, the 
aqueous phase was back extracted with DCM, and the combined organic fractions were dried over 
MgSO4, filtered, and conc. in vacuo to yield a clear, colorless, crude oil product. This crude product 
was purified by flash column chromatography (hexanes/EtOAc, 1/2) to yield a faintly yellow-
colored, viscous oil product 148axii (191.8 mg, 92% yield). [α]24D = +58.8 (c 2.15, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 6.89 – 6.81 (m, 3H), 6.25 (dd, J = 14.9, 11.0 Hz, 1H), 5.86 (t, J = 10.9 
Hz, 1H), 5.65 (dt, J = 14.5, 6.9 Hz, 1H), 5.31 (dd, J = 9.7, 1.6 Hz, 1H), 5.03 – 4.95 (m, 2H), 4.42 
(s, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.79 (d, J = 3.0 Hz, 3H), 3.77 (d, J = 3.0 Hz, 3H), 3.64 (qd, J = 
6.2, 3.0 Hz, 1H), 3.45 (t, J = 6.5 Hz, 2H), 3.02 – 2.93 (m, 3H), 2.30 (dqd, J = 9.9, 6.8, 3.1 Hz, 1H), 
2.17 (q, J = 7.3 Hz, 2H), 1.69 (p, J = 6.8 Hz, 2H), 1.54 (s, 3H), 1.00 (d, J = 6.6 Hz, 3H), 0.92 (d, 
J = 6.2 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H), 0.86 (s, 9H), 0.00 (s, 6H); 13C NMR (126 MHz, CDCl3) 
δ 164.69 (d, J = 6.2 Hz), 148.90, 148.44, 134.82, 132.75, 131.43, 130.99, 130.52, 128.47, 125.55, 
120.11, 110.87, 110.77, 84.88, 72.79, 71.39, 69.51, 55.84, 55.74, 52.99 (d, J = 6.2 Hz), 39.08, 
 
xii 55.1 mg scale: To a 5 mL RBF was added alcohol (147) (55.1 mg, 0.0967 mmol), THF (1.6 mL), 
and DMAP (1.0 mg, 8.19 μmol). This reaction mixture was put under N2, cooled to 0 °C, and 
stirred. Pyridine (0.0404 mL, 0.5 mmol) was added slowly, followed by dropwise addition of 
dimethyl (2-chloro-2-oxoethyl)phosphonate (0.74 mL, 0.4 M in THF), stirred 15 min @ 0 °C, 
warmed to rt and let run 20 h. By TLC, the reaction appeared to be approximately 50% complete. 
After concentrating the reaction down, and redissolving in THF (1.0 mL), DMAP (3.0 mg, 24.6 
μmol) was added. The mixture was stirred, put under N2 atmosphere, and cooled to 0 °C in an ice 
bath. Next, pyridine (0.044 mL, 0.55 mmol) and fresh dimethyl (2-chloro-2-oxoethyl)phosphonate 
(0.65 mL, 0.5 M) were both slowly added, in sequence, and the reaction mixture was allowed to 
stir for 15 min at 0 °C, let warm to rt and stir overnight. The crude product was purified via flash 
column chromatography (hexanes/EtOAc, 1/2), but DMAP and pyridine coeluted with the product. 
To remove these impurities, the product was dissolved in DCM, washed with HCl (1.0 N), CuSO4 
(0.1 M), and H2O (D.I.). After each wash, the aqueous phase was back extracted with DCM, and 
the combined organic fractions were dried over MgSO4, filtered, and conc. in vacuo to field the 
clear, colorless, crude oil product 148a (30.3 mg, 45% yield). 
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34.58, 34.08, 33.01, 29.46, 29.34, 25.79, 20.63, 17.99, 17.36, 16.19, 12.14, -4.48, -4.89; HRMS 
(ESI) m/z calcd for C36H61O9PSiNa+ [M+Na]+: 719.3715, found 719.3727; IR (thin film, cm-1) 
2955.7, 2930.2, 2855.4, 1735.3, 1593.7, 1516.7, 1463.4, 1419.3, 1374.1, 1266.5, 1185.5, 1157.8, 
1103.6, 1031.4, 963.8, 928.3, 837.1, 804.3, 774.4, 668.5, 431.0, 423.1, 415.6, 410.2. 
Scheme 2.13.5: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-14-
hydroxy-3,5,7-trimethyltetradeca-4,8,10-trien-6-yl 2-(dimethoxyphosphoryl)acetate (148) 
 
To a 5 mL RBF was added 148a (30.3 mg, 0.0435 mmol) followed by DCM/pH 7 buffer 
(18:1, 1.0 mL).68 This solution was stirred and cooled to 0 °C in an ice bath. To this solution was 
added DDQ (13 mg, 0.057 mmol), and the reaction mixture turned yellow. After 35 min, the 
reaction was deemed complete by TLC and was quenched with NaHCO3 (saturated, 3 mL) and 
Na2SO3 (1.0 M, 3 mL), and was stirred for an additional 10 minutes before transferring to a 
separatory funnel. The mixture was extracted with DCM (5 x 15 mL), and the combined organic 
fractions were dried over MgSO4, filtered, and conc. in vacuo to yield the crude product, which 
was purified via flash column chromatography (hexanes/EtOAc, 1/2) to yield the pure clear oil 
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product 148xiii (23.6 mg, >99% yield). [α]24D = +56.8 (c 3.595, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 6.34 – 6.22 (m, 1H), 5.89 (t, J = 11.0 Hz, 1H), 5.74 – 5.62 (m, 1H), 5.33 (d, J = 9.7 Hz, 
1H), 5.06 – 4.93 (m, 2H), 3.80 (dd, J = 11.2, 4.4 Hz, 6H), 3.66 (dd, J = 7.8, 5.2 Hz, 3H), 3.07 – 
2.90 (m, 3H), 2.38 – 2.26 (m, 1H), 2.19 (q, J = 7.2 Hz, 2H), 1.71 – 1.64 (m, 2H), 1.56 (d, J = 1.2 
Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 0.94 (d, J = 6.2 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 
2.7 Hz, 9H), 0.01 (s, 6H); 13C NMR (175 MHz, CDCl3) δ 164.7 (d, J = 6.2 Hz), 134.7, 132.7, 
131.4, 130.6, 128.5, 125.7, 84.9, 71.4, 62.1, 53.0 (dd, J = 6.5, 5.2 Hz), 39.1, 34.6, 33.9, 33.1, 32.1, 
29.1, 25.8, 20.6, 18.0, 17.4, 16.2, 12.2, -4.5, -4.9; HRMS (ESI) m/z calcd for C27H51O7PSiNa+ 
[M+Na]+: 569.3034, found 569.3039; IR (thin film, cm-1) 3440, 2957, 2930, 2857, 1736, 1472, 
1462, 1375, 1270, 1257, 1215, 1185, 1106, 1060, 1035, 982, 964, 928, 877, 837, 805, 774, 667. 
 
 
xiii 163 mg scale: Starting material 148a (163 mg) was dissolved in DCM/pH 7 buffer (18:1, 2.35 
mL). Next, DDQ (125 mg, 0.55 mmol) was added. After 2 h, the reaction didn’t appear done by 
TLC, so an additional portion of DDQ (25 mg, 0.11 mmol) was added, and the mixture was stirred 
an additional 30 min. As a side note, during the course of this reaction, the solution turned from 
green to blackish to yellowish-grey. The reaction mixture was quenched with NaHCO3 (saturated, 
5 mL) and Na2S2O3 (0.5 M, 5 mL),  and was stirred for an additional 10 minutes. Excess solvents 
were utilized, including including Na2SO3 (saturated), brine, H2O (D.I.), and DCM, but suspension 
of “yellow cloud” in sep. funnel difficult to remove. Therefore, it is important to note that Na2S2O3 
should be avoided, as it did not prove suitable to induce good seperation. Despite this, addition of 
EtOAc finally gave a good separation between the layers, allowing isolation of the organic and 
aqueous fractions. The combined organic fractions were dried over MgSO4, filtered, and 
concentrated in vacuo to yield the crude product, which could be purified via flash column 
chromatography (EtOAc) to yield the pure viscous brown oil product 148 (159.8 mg, 80% yield). 
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Scheme 2.13.6: Synthesis of (2R,3S,4E,6R,7S,8Z,10E)-2-((tert-butyldimethylsilyl)oxy)-3,5,7-
trimethyl-14-oxotetradeca-4,8,10-trien-6-yl 2-(dimethoxyphosphoryl)acetate (149) 
In a 5 mL conical RBF was added alcohol 148 (20.0 mg, 0.366 mmol), DCM (0.85 mL), 
NaHCO3 (3.0 mg, 0.036 mmol), and DMP (25 mg, 0.059 mmol). The mixture bubbled and turned 
a white-greyish color while stirring. After 2 h, the reaction was complete by TLC and was 
quenched with NaHCO3 (saturated solution, 10 mL) and Na2S2O3 (0.5 M, 10 mL). The aqueous 
phase was extracted with DCM (3 x 15 mL), and the combined organic fractions were washed with 
brine (40 mL), dried over MgSO4, and conc. in vacuo to yield the crude product. This crude product 
was filtered through a short column of silica gel (hexanes/EtOAc, 1/2) to yield 149 as a yellow oil, 
which was used immediately in the macrocyclization reaction (19.5 mg, 98% yield). 1H NMR (500 
MHz, CDCl3) δ 9.76 (t, J = 1.4 Hz, 1H), 6.33 – 6.24 (m, 1H), 5.85 (t, J = 11.0 Hz, 1H), 5.69 – 5.56 
(m, 1H), 5.32 (d, J = 9.6 Hz, 1H), 5.04 (t, J = 10.6 Hz, 1H), 4.97 (d, J = 9.0 Hz, 1H), 3.78 (dd, J = 
11.2, 2.9 Hz, 6H), 3.63 (qd, J = 6.2, 3.3 Hz, 1H), 2.97 (dd, J = 21.7, 0.7 Hz, 3H), 2.53 (t, J = 7.0 
Hz, 2H), 2.42 (q, J = 7.1 Hz, 2H), 2.37 – 2.23 (m, 1H), 1.54 (d, J = 1.2 Hz, 3H), 1.00 (d, J = 6.6 
Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.00 (s, 6H); 13C NMR 
(125 MHz, CDCl3) δ 201.6, 164.7 (d, J = 6.4 Hz), 132.8, 132.6, 131.5, 131.4, 128.0, 126.4, 84.8, 
71.4, 53.0 (dd, J = 6.5, 2.4 Hz), 43.2, 39.1, 34.7, 34.1, 33.0, 25.8, 25.3, 20.7, 18.0, 17.4, 16.3, 12.2, 
-4.5, -4.9. 
2.14 Extended-chain analog synthesis (procedures & analytical/spectral data) 
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Scheme 2.14.1: Synthesis of 4-(2,6-dioxopiperidin-4-yl)butanal (152) 
 In a 50 mL round-bottomed flask was added aldehyde 19 (150.2 mg, 0.968 mmol)64 in 
anhydrous DCM (4.84 mL) to give a white suspension. The mixture was cooled to 0 °C under N2, 
and 2-(triphenyl-λ5-phosphanylidene)acetaldehyde (760 mg, 2.50 mmol) suspended in DCM (3 x 
1.6 mL) and added slowly to give an orange-colored solution. The obtained solution was warmed 
to rt and stirred overnight for 25.5 h (under N2). A small sample of the reaction was checked by 
NMR, showing the reaction was incomplete,xiv so additional 2-(triphenyl-λ5-
phosphanylidene)acetaldehyde (176 mg, 0.57 mmol)xv dissolved in 1.5 mL anhydrous DCM was 
added. The reaction was then stirred for an additional 18.5 h. The final reaction mixture was 
concentrated in vacuo to yield a red residue. This crude product was partially purified via flash 
column chromatography through a short column (EtOAc), to remove the excess 2-(triphenyl-λ5-
phosphanylidene)acetaldehyde, but Ph3PO co-eluted with the desired product 152a. This crude 
material was carried onto the next step without further purification. 
In a 50 mL round-bottomed flask was added crude 152axvi in THF (12.75 mL) to give an 
orange solution. The flask was purged with argon gas, 10% wt. Pd/C (300 mg) was quickly added, 
and the flask was purged with H2. The reaction was stirred under positive H2 pressure (via balloon) 
overnight for 18.5 h. The resultant reaction mixture was filtered through celite, and the filter cake 
was rinsed with EtOAc three times. The resulting solution was concentrated in vacuo to yield a 
 
xiv By NMR: Approximately 77% converted to product and 23% remaining starting aldehyde. 
xv Total amount used of 2-(triphenyl-λ5-phosphanylidene)acetaldehyde: 936 mg, 3.07 mmol. 
xvi Crude weight not recorded, since a significant amount of impurity was present (which may 
vary). 
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white crude solid. The crude product was purified by flash column chromatography 
(DCM/methanol/, 95/5 to 93.5/6.5)xvii to yield the pure white solid product 152 (23.1 mg, 13% 
yieldxviii across 2 steps). 1H NMR (700 MHz, CDCl3) δ 9.76 (t, J = 1.3 Hz, 1H), 8.47 (s, 1H), 2.71 
(dd, J = 17.1, 4.2 Hz, 2H), 2.48 (td, J = 7.1, 1.3 Hz, 2H), 2.31 – 2.22 (m, 2H), 2.19 – 2.09 (m, 1H), 
1.70 – 1.62 (m, 2H), 1.44 – 1.38 (m, 2H); 13C NMR (176 MHz, CDCl3) δ 201.39, 172.17, 43.37, 
37.61, 34.08, 30.24, 18.84; HRMS (ESI) m/z calcd for C9H13NO3+ [M+Na]+: 206.0788, found 
206.0785; IR (thin film, cm-1) 3200, 3091, 2944, 2869, 2733, 1724, 1684, 1377, 1270, 1146, 875. 
 
Scheme 2.14.2: Synthesis of 4-((4R,7S,E)-4-hydroxy-7-methyl-9-((2R,3S,4Z,6E,10E)-3-
methyl-12-oxooxacyclododeca-4,6,10-trien-2-yl)-6-oxodec-8-en-1-yl)piperidine-2,6-dione 
(153) 
 
xvii Multiple columns were used, trying EtOAc as a solvent at first, with poor separation. The purest 
fractions were carried forward after each column. The best solvent system was finally identified 
and is reported to separate the pure product. 
xviii Unoptimized yield reported. 
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In a 10 mL round-bottomed flask chlorotrimethylsilane (0.053 mL, 0.417 mmol) and 
triethylamine (0.058 mL, 0.417 mmol) were added to a solution of 33 (12.6 mg, 0.042 mmol) in 
THF (1.46 mL) at -78 °C to form a colorless solution. Next, LiHMDS (0.104 mL, 0.104 mmol, 
1.0 M in THF) was added dropwise to give a colorless solution. The reaction mixture was stirred 
at -78 °C for 1.5 hour and was confirmed complete by TLC [Rf of (33) = 0.3 and Rf of (50) = 0.6, 
both in D.S. of hexanes/EtOAc (4/1)]. The reaction mixture was quenched with pH 7 buffer (5 
mL), and warmed to rt, while stirring, over 10 minutes. The aq layer was back extracted with DCM 
(3 x 3 mL), and the combined organic layers were dried over MgSO4, filtered, and conc. in vacuo, 
to yield the resulting crude yellow oil 50, which was stored frozen in benzene prior to the next 
steps and used without further purification. 
In a 15 mL conical round-bottomed flask was added 50xix (15.7 mg, crude), 152xix (9.6 mg, 
0.053 mmol), and molecular sieves (4Å, ca. 150 mg) in dry propionitrile (575 μL) to give a yellow 
suspension. The reaction was put under N2, cooled to -78 °C, and stirred for 5 minutes. Next, 93xx 
(23.3 mg, 53 μmol) dissolved in propionitrile (145 μL) was added dropwise, resulting in a yellow 
suspension. The reaction was stirred overnight in the cryocool at -78 °C (dry ice used to keep cool). 
After 23 h, the reaction was checked by TLC and LCMS, which showed the reaction to be 
incomplete. Fresh catalyst was generated and was dissolved in propionitrile (250 μL). After an 
additional 14 h (37 h total reaction time), the reaction was quenched with conc. NaHCO3 (3 mL). 
The mixture was warmed to rt and the aqueous phase was extracted with DCM (3x5 mL). The 
combined organic layers were dried over MgSO4, filtered, and conc. in vacuo to yield the crude 
 
xix Azeotroped in dry benzene three times prior to reaction. 
xx Prepared same as before during the synthesis of lactimidomycin (6). 
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oil 153a (7.5 mg, 13 μmol, 32.0% crude yield), which was submitted to the next reaction without 
further purification. 
In a 15 mL falcon vialxxi was added 153a (23 mg, crude) in THF (7.5 mL) to form a 
suspension. Next, the reaction was put under nitrogen, stirred, and cooled to 0 °C, and buffered 
HF-pyridine complex solution (0.75 mL, prepared by mixing THF [723.5 μL], pyridine [269 μL], 
and HF-pyridine [54 μL] in a separate 15 mL falcon vial) was added slowly. The mixture was 
stirred for 2 h at 0 °C and warmed to rt for 30 min to complete the reaction. The reaction mixture 
was diluted with DCM (30 mL) and transferred to a plastic separatory funnel. The mixture was 
washed with sat NaHCO3 (15 mL) and CuSO4 (0.1 M, 3 x 15 mL), dried over MgSO4, filtered, 
and conc. in vacuo. The resulting residue was purified via a short pipette column (EtOAc/hexanes, 
3/1), giving the white-colored product 153 (6.1 mg, 30% yield, 2.6:1 dr at the C-17 position prior 
to further purification). This material was then further purified via a series of short pipette columns 
(EtOAc/hexanes, 3/1) to give a sample for characterization and biological testing. 1H NMR (400 
MHz, C6D6) δ 7.50 (br s, 1H), 6.44 (ddd, J = 15.5, 10.3, 4.9 Hz, 1H), 6.07 (dd, J = 10.8, 10.8 Hz, 
1H), 5.68 (dd, J = 15.5, 10.7 Hz, 1H), 5.59 (d, J = 4.8 Hz, 1H), 5.49 (d, J = 16.1 Hz, 1H), 5.23 (d, 
J = 9.7 Hz, 1H), 5.16 – 5.06 (m, 2H, overlap), 3.90 (dd, J = 14.3, 7.1 Hz, 1H), 3.26 – 3.10 (m, 2H, 
overlap), 2.90 (br s, 1H), 2.36 (dd, J = 17.5, 8.9 Hz, 1H), 2.18 – 2.06 (m, 3H), 2.02 – 1.90 (m, 2H), 
1.70 (d, J = 1.3 Hz, 3H), 1.54 – 1.43 (m, 4H), 1.40 – 1.28 (m, 1H), 1.26 – 1.08 (m, 3H),1.04 (d, J 
= 6.8 Hz, 3H), 1.04 – 0.95 (m, 1H), 0.85 (d, J = 6.8 Hz, 3H), 0.78 – 0.63 (m, 2H); 13C NMR (126 
MHz, C6D6) δ 211.21, 171.13, 166.07, 146.53, 134.78, 134.08, 131.74, 129.86, 129.78, 128.35, 
82.74, 67.28, 47.52, 46.85, 37.68, 37.64, 36.57, 36.39, 34.53, 32.27, 31.26, 29.99, 22.59, 17.56, 
 
xxi Reaction and buffered solutions were run and prepared, respectively, in plastic, falcon vial 
containers to avoid reacting HF-Pyridine with glass containers. 
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16.02, 15.14; HRMS (ESI) m/z calcd for C28H39NO6+ [M+Na]+: 508.2670, found 508.2664; IR 
(thin film, cm-1) 3422, 2925, 2854, 1716, 1700, 1684, 1653, 1540, 1456, 1259, 1171, 1031. 
Figure 2.14.1: MDA-MB-231 2D 
 
Figure 2.14.2: MDA-MB-231 3D 
 
Figure 2.14.3: Human mammary epithelial cells 
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Figure 2.14.4: MDA-MB-231 cell growth 2D with lactimidomycin (6) 
 
Figure 2.14.5: MDA-MB-231 3D cell growth with lactimidomycin (6) 
 
Figure 2.14.6: Human mammary epithelial cells with lactimidomycin (6) 
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Chapter 3: Synthetic studies towards the convergent, scalable total synthesis 
of natural tricyclic diterpenoid products and analogs in pursuit of novel 
anticancer therapuetics 
3.1 Diterpenoid natural product scaffolds: pimeranes, isopimeranes, kauranes, and more 
Pimeranes (154) and isopimeranes (155) are members of an abundant group of plant and 
fungal diterpenes,1, 2 some of which are deeply rooted in traditional Asian medicinal treatments.3, 
4 Characteristic features of these compounds include a tricyclic ring system and two quaternary 
stereocenters at the C10 and C13 positions. The members of pimarane and isopimarane families 
possess a range of biological activities, and both enantiomeric forms of these types natural products 
have been isolated and identified to be bioactive. In addition, similar structural motifs are present 
in a related class of tetracyclic terpenes, kauranes (156),5, 6 a group that exhibits anti-bacterial, 
anti-tumor, and antimalarial activity. Remarkably, despite these biological activites, relatively 
few asymmetric total synthetic strategies have been developed in the construction of these 
scaffolds in their higher oxidation states, as most reported analogs of these compounds arise from 
biosynthetic or semi-synthetic methodologies; therefore, it is quite difficult to form structural 
analogs containing varying degrees of oxidation, units of unsaturation, and stereoisomeric forms.7-
14 
Figure 3.1.1: Selected tricyclic diterpene scaffolds: pimerane, isopimerane, and kaurane-type 
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3.2 Biosynthesis of isopimerane and pimerane-type scaffolds (1-2) 
The exact biosynthetic pathways towards specific diterpene natural products are yet to be 
fully described, as there are a multitude of enzymes that have yet to be isolated and identified.15 
Therefore, a more general review on the biosynthetic pathway leading to the formation of 
molecules structurally similar to 1 and 2 will be described. 
Dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP) are the two 
substrates used in the biosynthesis of diterpenes (Scheme 3.2.1).16 DMAPP and IPP condense to 
form geranyl pyrophosphate (GPP), then GPP and IPP form farnesyl diphosphate (FPP), and 
finally FPP and IPP form geranylgeranyl diphosphate (GGPP) in a series of reactions catalyzed by 
their enzymatic partners, geranyl diphosphate synthase (GPPS), farnesyl diphosphate synthase 
(FPPS), and geranylgeranyl diphosphate synthase (GGPPS), respectively. The compound GGPP 
is of extreme importance, given that it is the starting point from which all diterpenes are 
biosynthetically formed. 
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Scheme 3.2.1: Biosynthesis of GGPP from simple substrates DMAPP and IPP 
Derivitization of GGPP into various dirtenes via biosynthetic pathways are induced by one 
of several enzymes commonly referred to as cyclases (or synthases). As there are many different 
cyclases still yet to be isolated and identified, it is easier to categorize the transformations by their 
cyclization pathway, of which two main mechanistic pathways can be observed, Type A and B 
cyclizations which are defined by how they initiate the cyclization. Type A cyclizations are 
initiated by the ionization of a diphosphate, and Type B cyclizations are initiated by the protonation 
at the C14-C15 double bond. 
It is important to note, depending on the cyclase, an A and/or B pathway can take place, or 
a A-B or B-A dicyclization can take place, all enzymatically promoted by a single cyclase. To 
further complicate things, some dicyclizations are promoted by two different cyclases which are 
working on only the first or second cyclization. As there are a variety of different possible enzymes 
present in biological system, the number of diterpenes is accordingly increasingly complexe, 
considering that the monocyclized, dicyclized products can undergo a variety of different cationic 
rearrangements, transformations via later stage oxidation via oxidase enzyme(s), and the 
conditions present in the biosynthetic system (presence of acid/base, etc.). 
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Scheme 3.2.2: Type B1 cyclization via the chair-chair confirmation to form CPP 
  In the production of isopimarane- and pimarane-skeleton-containing natural products, most 
likely a Type B-Type A series of cyclizations takes place via two distinct mechanistic pathways.  
First, GGPP undergoes a cyclase-promoted Type B1 cyclization (chair-chair confirmation) 
via the protonation of the C14-C15 bond and subsequent cationic rearrangment of 157 to form the 
normal form of CCP (Scheme 3.2.2). Second, the newly formed CCP undergoes a cyclase-
promoted Type A cyclization initiated via ionization of its diphosphate to form the C17 
carbocation-containing intermediate 158 (Scheme 3.2.3). This intermediate then undergoes the 
cyclization as the C13 carbon (double bond) attacks C17 carbocation from either the re- or si-face, 
leading to the formation of carboncation intermediates 159 (isopimerane-type) or 160 (pimerane-
type), respectively, which can further be further transformed via further enzymatically and/or 
thermodynamically driven pathways. In particular, oxidases are responsible for installing units of 
oxydation at various stereocenters; however isolation and identification of these enzymes along 
with identification of the exact biosynthetic pathway of many diterpenes, a large class of 
compounds which continues to grow as new derivatives are still being discovered. 
 117 
 
 
Scheme 3.2.3: Type A cyclization via OPP ionization and rearrangement to form 10 and 11 
3.3 C-H functionalization at the C20 position of various natural products 
 
Scheme 3.3.1: Previous work on promotion of the C-H oxidation at the C20 (or similarly 
positioned) methyl group of various terpenoids and steroids 
 To date very few viable chemical transformations exist that can selectively oxidize the 
desired C20 position of pimerane and isopimerane skeleton directly in forming structural 
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diveritives. Barton and co-workers have discussed a method employing photolysis of a nitrite 
group to produce the desired oxygenation at a similar position on their norsteroids (Scheme 
3.3.1).17 Later, Borbett and Wilkins found they could functionalize certain methyl groups found in 
isopimarane and hopanol derivatives. Both of these methods require UV radiation of a nitrite ester 
to an oxime, which would then form the corresponding hemiacetal;16 furthermore, they all suffer 
from the use of toxic and functional group intolerant reagents. Many structural motifs in these 
compounds are not stable in the presence of oxidative radical species. 
3.4 General Michael and double-aldol cascade utilized in the synthesis of steroid and 
terpene scaffolds 
 
Scheme 3.4.1: Nagorny et al. general approach to forming various terpenoid scaffolds 
As previously discussed, the formation of multiple highly substituted stereocenter in a single 
step is rather limited. One versatile reaction that has been underutilized is that of the asymmetric 
intramolecular Michael reaction to construct vicinal quaternary and tertiary stereocenters. Previous 
examples of these are limited and did not provide an efficient enantioselective formation of the 
desired Michael adduct for the desired substrates. 
We has previously shown that cyclic ketoesters 169 and enones 170 can undergo a Lewis 
acid-catalyzed Michael addition to 171, followed by a double aldol cascade cyclization can lead 
to the various terpenoid-type products (172) with high diastereoselectivity (and enantioselectivity 
if the correct chiral ligands are used on copper[II]) and high yields (Scheme 3.4.1). 
 
 119 
 
3.5 Selected diterpene-core containing natural products of interest 
 
Figure 3.5.1: Diterpene skeletons and their biologically active derviatives. 
Today both mammalian and plant-based steroids make up a significant portion of the top 
selling pharmaceuticals18 In order to promote greater selectivity of new therapeutics, researchers 
have increasingly focused more on chiral molecules over “flat” molecules (which lack such 
stereochemistry).19 Inserting stereocenters, especially quaternary ones, has shown marked 
improvements in improving efficacy and reducing unwanted side effects of various drugs.20 
Synthesis of tricyclic poly-oxygenated diterpenes and related skeletons bearing multiple 
quaternary stereocenters is a common goal among research groups, due to the difficulty in 
producing such constrained and complex structures with multiple stereogenic centers.21 Some of 
these (iso)pimerane-containing natural products include sphaeropsidins A (173) and C (174), 
aspergilone A (175), compactone (176), and aspewentin A (177) and B (178). 
Sphaeropsidin A (173) and C (174) are fungal metabolites produced by Diplodia cupressi 
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and Smardaea sp. AZ0432. In particular, sphaeropsidin A (173) has been found to inhibit the 
migration of triple negative breast cancer cells (MDA-MB-231, IC50 = 1.5 μM). In addition, both 
173 and 174 have been shown to exhibit antimicrobial activity against Xanthomonas oryzae, which 
is the leading cause of blight, a disease of rice plants which negatively impacts the crop yields, 
causing major issues in the food supply across the globe.8, 9, 22 Aspergilone A (175) is a cytotoxic 
molecule structurally similar to 173 (shifted site of oxygenation).23 Compactone (176)24 may serve 
as an important intermediate to synthetically accessing kaurane(156)-containing or interrelated 
scaffolds. Aspewentin A (177) and B (178) have been reported to contain interesting biological 
activites against different microorganisms. In particular, the importance of the aromatic ring in 177 
has been suggested to promote different bioactivity in these norisopimarane diterpenes, in 
particular against the zooplankton (Artemia saline) over the other marine phytoplanktons.25 
Development of a rapid synthetic route to any of these natural products would allow access to 
various diterepene-based truncated analogs. 
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3.6 Retrosynthetic analysis of the diterpenoid core (179) 
  
Scheme 3.6.1: Final retrosynthetic analysis in forming core diterpene towards natural 
products 
Retrosynthetically, we envisioned forming the diterpenoid core (179) via a key Michael-
double aldol sequence, through which ketoester 181 and aldehyde-enone 182 would be first treated 
with a lewis acid to promote a Michael addition to form aldehyde 180, followed by treatment with 
an optimized base to promote the diastereoselective double aldol reaction to produce 179 (Scheme 
3.6.1). Upon beginning our studies, the formation of a cyclic gem-dimethyl ketoesters 182 was 
predicted to be simple; however, the assymetric synthesis of 182 proved a more formidable task 
than was initially envisioned. 
After several chiral auxilaries derived from tiglic acid and/or crotonyl chloride starting 
materials, it was discovered the best was to access this chiral aldehyde-enone 182 was through its 
precursor alcohol 183 via deprotection of the silyl group to the diol intermediate, followed by a 
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dioxidation. Using 184, a diastereoselective alkylation was predicted to introduce the final methyl 
group of the quaternary stereocenter, which, upon removal of the auxilary via reductive conditions 
was predicted to form 183. Compound 184 is accessible via a diastereoselective alkylation reaction 
of 186, derived from crotonyl chloride and Myer’s auxilary, and alkyl halide 185, derived from a 
cross metathesis reaction of 187 and 188 followed by subsequent halogenation. 
3.7 Synthesis of the ketoesteres 173a and 173b 
 
Scheme 3.7.1: Synthesis of ketoesters 173a and 173b from 2-methylcyclohexan-1-one 
A simple series of known reactions were used to form 173a and 173b from 2-
methylcyclohexane-1-one over 2 steps, and both compounds were prepared in gram scale 
quantities. 
3.8 Rapid preparation of iodide 192 
The synthesis of a key iodide intermediate 192 using a rapid sequence (Scheme 3.8.1) was 
achieved in only 3 linear steps (4 steps total). 
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Scheme 3.8.1: Synthesis of key TBS-protected iodide fragment 192 
First, the mesylate 189 and TBS-protected alcohol 19026 were prepared via previously 
detailed procedures. With these two protected components in hand, a Grubb’s cross methathesis 
was utilized to form 191, which was converted via a Finkelstein SN2 displacement reaction to 
form iodide 192. 
3.9 Synthesis of the quaternary carbon-containing 182 
Despite the push for green chemistry and atom-economic methodology, chiral auxiliaries 
have become known for being generally reliable and versatile, through enabling the synthesis of a 
large number of enantiomerically pure compounds in a time-efficient manner. Because of this, they 
are often the method of choice, especially in the early phases of drug development.27 28, 29 
Originally, we tested pseudoephedrine (Figure 3.9.1) as our auxilary in final reaction 
sequence, demonstrating the reactions with the R=Me containing intermediates proceeded cleanly 
and that the chemistry was possible; however, based on the prior precedent from Movassaghi’s 
group, a less than desirable (>6:1) or from pseudoephedrine-containing intermediates could be 
enhance to 29:1 if pseudoephenamine-containing intermediates, are employed. 
Figure 3.9.1: Myer’s auxilaries - pseudoephedrine vs. pseudoephenamine 
 
 124 
 
The simple to prepare and recyclable Myer’s auxilary, (R,R)-pseudoephenamine (Figure 
3.9.1) was selected as the auxilary of choice for the optized route.30 This novel auxilary was 
selected as it had previously been shown to promote a highly stereoselective series of alkylations 
in the formation of typically difficult to form quaternary stereocenters.30, 31 
  
Scheme 3.9.1: Scalable synthesis of chiral intermediate 182 
In this reaction sequence, the formly synthesized iodide 192 was utilized as the electrophile 
for the addition with the auxiliary-containing 193, which was available from R,R-
pseudoephenamine following previously published procedures.32, 33 The product of this first 
alkylation 194 was then submitted to another alkylation reaction with MeI in the prescence of 
DMPU, LDA, and LiCl to form 195. This product was converted into the diol 196 via a two-step 
reduction/oxidation sequence. Finally, 196 was subjected to oxidation using DMP to form the 
chiral substrate 182. Upon completion of optimizing the alkylation sequence to build the chiral 
quatenary stereocenter, this protocol was repeated on a larger scale by Danielle Singleton. 
3.10 Model studies towards the synthesis of the isopimarane-type core diterpene 
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We have also developed a Michael (followed by double aldol condensation; not shown) 
sequence employing a copper (II) catalyst with a chiral box ligand followed by treatment with a 
base has been developed and tested (Scheme 3.10.1). 
 
Scheme 3.10.1: Highly enantioselective chiral Cu(II) promoted Michael reaction 
In order to demonstrate the feasibility of the Michael reaction leading to the formation of 
182, a series of model studies were conducted. First, ketoester 173a was reacted with commercially 
available (E)-7-oxooct-5-enal with Cu(OTf)2 under neat conditions. As a result, the corresponding 
product 197 was isolated in ca. 90% yield. This demonstrates that the reaction is tolerant to the 
gem-dimethyl substitution on the ketoester 173a. 
 
Scheme 3.10.2: Michael reaction of gem-dimethyl ketoester 173a and commercially available 
unfunctionalized trans-3-octen-2-one 
Furthermore, readily available ketoester 198 and enone 199 were reactioned with Cu(OTf)2 
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under neat conditions.i As a result, the corresponding product 200 was isolated in ca. 75% yield 
with a d.r. of 4:1. This demonstrates that the reaction is tolerant to the dimethyl substitution next 
to the aldehyde functionality on the enone 199. 
 
Scheme 3.10.3: Michael reaction of unfunctionalized ketoester 192 and dimethyl aldehyde-
enone 199 
With these promising studies, further model studies were attempted. In order to optimize the 
enantioselectivity of the Michael reactions without having to use valuable chiral starting material 
182, model studies were conducted employing a commercially available un-functionalized enone. 
Accordingly, the racemic reaction was testedii between the of functionalized non-chiral enone 199 
and ketoester 173a.34, 35 However, instead of sole formation of the Michael adduct, the cyclized 
product 204 was acquired in 56% yield as a single diastereomer. 
  
 
i Conducted by Dr. Nathan Cichowicz 
ii Conducted by Danielle Singleton 
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Scheme 3.10.4: Racemic reaction with functionalized enone and closing of cyclized core with 
LiHMDS 
This result was encouraging in that there was concern that the aldehyde in our chiral substrate 
would interfere with the formation of the Michael adduct, instead it was observed to assist in the 
formation of the desired core, and spontaneous cyclization was observed to 204a. At this time, few 
conditions for the second cyclization had been tested, but the best results were obtained using 
LiHMDS. Having obtained moderate yields of the desired tricyclic core 205, we were assured that 
this method would be appropriate for the chiral substrate.  
3.11 Summary 
The synthesis of isoterpene-core intermediate 182 is the subject of ongoing studies in the 
Nagorny group. The synthesis of 182 should allow access to various diterpene-type natural 
products (173-178). It is noteworthy that using S,S-(-)-pseudoephenamine, the enantiomer of the 
starting R,R-(+)-pseudoephenamine (Figure 3.9.1), pimarane-type compounds (1), rather than 
isopimarane-type compounds (2), could be also obtained. 
Besides the polyoxygenated diterpenes, a number of different alkaloid families of natural 
products can potentially be accessed including hetidine, hestisine, aza-atisine and atasine sub- 
classes of diterpene-alkaloids utilizing similar starting materials. 
 128 
 
  
Scheme 3.11.1: Proposed routes for accessing various isopimarane derivatives via the cyclic 
diterpene intermediate 182 
The described synthetic studies have contributed towards the eventual development of a 
synthetic strategy utilizing both a novel chiral auxilary and an asymmetric strategy in the synthesis 
of these polycyclic molecules containing multiple quaternary stereocenters. The results of this 
reasearch are significant in that this privileged tricyclic diterpenoid class of biologically active 
compounds could be reached in a short, total synthetic manner, potentially broadening the scope 
of bioactive molecules that can be developed and improving the availability of these compounds 
and structurally related-analogs for biological evaluation as potential targets in the pursuit of new 
and novel anticancer therapeutics.  
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Chapter 3: Supporting Information 
3.12 General reaction methods 
All reactions were carried out under an atmosphere of nitrogen in flame– or oven–dried 
glassware with magnetic stirring, unless otherwise noted. Air–sensitive reagents and solutions 
were transferred via syringe or cannula and were introduced to the apparatus through rubber septa. 
Intermediates used in water sensitive reactions were azeotroped in toluene or benzene prior to use. 
Reactions were cooled via external cooling baths: ice water (0 °C), dry ice–acetone (-78 °C), or 
Neslab CB 80 immersion cooler (-20 to -78 °C). Heating was achieved by use of a silicone bath 
with heating controlled by an electronic contact thermometer. Deionized water was used in the 
preparation of all aqueous solutions and for all aqueous extractions. Solvents used for extraction 
and flash column chromatography were ACS or HPLC grade. Reagents were purified prior to use 
following the guidelines of Perrin and Armarego.36 Tetrahydrofuran (THF), dichloromethane 
(DCM), toluene and diethyl ether (Et2O) were filtered through a column (Innovative Technologies) 
of activated alumina under nitrogen atmosphere. Chloroform (CHCl3) and deuterated chloroform 
(CDCl3) were filtered through a column of basic alumina and magnesium sulfate prior to use with 
acid sensitive materials. Purification of the reactions mixtures was performed by flash column 
chromatography using SiliCycleSiliaFlash P60 (230-400 mesh) silica gel. 4Å molecular sieves 
were pre-activated before use. 
3.13 Spectral data acquisition 
1H NMR spectra were recorded on Varian vnmrs 700 (700 MHz), Varian vnmrs 500 (500 
MHz), Varian INOVA 500 (500 MHz) or Varian MR400 (400-401 MHz) spectrometers and 
chemical shifts (δ) are reported in parts per million (ppm) with solvent resonance as the internal 
standard (CDCl3 at δ 7.26, C6D6 at δ 7.15). Data are reported as follows (s = singlet, br s = broad 
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singlet, d = doublet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, ddd 
= doublet of doublet of doublets, dddd = doublet of doublet of doublet of doublets, dqd = doublet 
of quartet of doublets, t = triplet, q = quartet, qd = quartet of doublets, m = multiplet; coupling 
constant(s) in Hz; integration). Proton-decoupled 13C NMR spectra were recorded on Varian vnmrs 
700 (175 MHz), Varian vnmrs 500 (125-126 MHz), Varian INOVA 500 (125-126 MHz) or Varian 
MR400 (100 MHz) spectrometers and chemical shifts (δ) are reported in ppm with solvent 
resonance as the internal standard (CDCl3 at δ 77.000, C6D6 at δ 127.683). High resolution mass 
spectra (HRMS) were recorded on MicromassAutoSpecUltima or VGtd (Micromass) 70-250-S 
Magnetic sector mass spectrometers in the University of Michigan mass spectrometry laboratory. 
Infrared (IR) spectra were recorded as thin films on NaCl plates on a Perkin Elmer Spectrum BX 
FT-IR spectrometer. Absorption peaks were reported in wavenumbers (cm-1). Optical rotations 
were measured in a solvent of choice on a JASCO P-2000 or Autopol III digital polarimeter at 589 
nm (D-line) and reported as follows: [α]TEMPD (c = g/100 mL, solvent). Circular Dichroism was 
measured in spectroscopic grade ethanol on a JASCO J-815 Circular Dichroism Spectrometer. 
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Scheme 3.13.1: Synthesis of (E)-5-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl 
methanesulfonate (191) 
In a small oven-dried conical rbf (10 mL) was added mesylate-protected 18937 (227 mg, 1.44 
mmol) and TBS-protected 19026 (545 mg, 2.92 mmol), a reflux condenser was attached, and the 
mixture was put under N2. Next, Grubb's II (19.4 mg, 0.023 mmol) dissolved in dry DCM (2.5 
mL) was added carefully via syringe. The mixture was refluxed at 40 °C for 12 h, cooled to rt, and 
carefully concentrated in vacuo to approximately 0.5 mL in volume. The crude mixture was 
purified via flash column chromatography (hexanes/EtOAc, 90/10 to 85/15) to yield the pure 
volitile oil product 191 (337 mg, 76 % yield); 1H NMR (400 MHz, CDCl3) δ 5.72 – 5.46 (m, 2H), 
4.36 – 4.18 (m, 3H), 3.00 (d, J = 1.2 Hz, 3H), 2.51 – 2.43 (m, 2H), 1.19 (d, J = 6.3 Hz, 3H), 0.89 
(s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); HRMS (ESI) m/z calcd for C13H28O4SSiH+ [M+H]+ 309.1550, 
found 309.1548; HRMS (ESI) m/z calcd for C13H28O4SSiNa+ [M+Na]+ 331.1370, found 331.1367. 
 
Scheme 3.13.2: Synthesis of (E)-tert-butyl((6-iodohex-3-en-2-yl)oxy)dimethylsilane (192) 
In an oven-dried RBF, add sodium iodide (0.840 g, 5.60 mmol) and put the reaction under 
N2 with a reflux condenser on top. Next, compound 191 (0.150 g, 0.49 mmol) dissolved in acetone 
(3.03 mL) was added via syringe. The resulting mixture was refluxed at 57 °C for 2 hr and then let 
cool to rt. The reaction mixture was filtered through a fritted glass funnel, rinsed with acetone (3 
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times), and conc. in vacuo. The obtained material diluted with Et2O (50 mL) and washed with 
Brine (2 x 25 mL). The combined organic fractions were dried over MgSO4, filtered, and carefully 
conc. in vacuoiii to yield the crude transparent, yellow-colored oil (156.6 mg crude). The crude 
product was purified via flash column chromatography (hexanes/Et2O, 50/50) to yield the pure 
product was obtained as a clear, colorless, volitile oil, 192 (129 mg, 78% yield). 1H NMR (400 
MHz, CDCl3) δ 5.65 – 5.42 (m, 2H), 4.27 (p, J = 6.1 Hz, 1H), 3.15 (t, J = 7.3 Hz, 2H), 2.64 – 2.49 
(m, 2H), 1.20 (d, J = 6.3 Hz, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.06 (s, 3H). LRMS (ESI) m/z calcd 
for C12H25IOSiNa+ [M+Na]+ 363.06.iv 
  
Scheme 3.13.3: Synthesis of (E)-7-((tert-butyldimethylsilyl)oxy)-N-((1S,2S)-1-hydroxy-1-
phenylpropan-2-yl)-N-methyl-2-vinyloct-5-enamide (S2) 
To a suspension of lithium chloride (118 mg, 2.78 mmol) in THF (0.489 mL) at -78 °C was 
added 2,2,6,6-tetramethylpiperidine (0.180 mL, 1.06 mmol) dropwise via syringe. A solution of 
n-BuLi (0.59 mL, 0.95 mmol, 1.6 M in THF) was added via syringe, and the resulting mixture was 
warmed to 0 °C. After 20 min, an ice-cooled solution of S138 (108 mg, 0.46 mmol) in THF (1.22 
mL) was added via cannula. The transfer was rinsed with additional THF (2 x 0.204 mL). After 10 
min, the reaction mixture was cooled to -78 °C. After 10 min, iodide 192 (314.3 mg, 0.924 mmol) 
 
iii Material was somewhat volatile; cooled rotovap bath down and avoided using high vacuum 
when concentrating in vacuo. 
iv “after several ionization techniques… have not yet been successful in getting a representative 
spectrum.” – Paul Lennon. 
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was added via syringe followed by a rinse with THF (50 uL). After 40 min, the reaction mixture 
was warmed to 0 °C. After 4.5 h, saturated aqueous ammonium chloride solution was added to 
quench the lithium alkoxide salts. Brine and ethyl acetate were added, and the layers were 
seperated. The aqeuous layer was futher extracted with ethyl acetate (2x). the combined organic 
layers were dried over anhydrous MgSO4, were filtered, and were concentrated under reduced 
pressure. The resudue was purified by flash column chromatography (hexanes/EtOAc, 65/35 to 
60/40) to yield the pure product S2. 1H NMR (700 MHz, CDCl3) δ 7.40 – 7.26 (m, 5H), 5.84 – 
5.70 (m, 1H), 5.58 – 5.34 (m, 2H), 5.18 – 5.01 (m, 2H), 4.69 – 4.07 (m, 4H), 3.49 – 3.07 (m, 1H), 
2.96 – 2.80 (m, 3H), 2.04 – 1.79 (m, 3H), 1.65 – 1.47 (m, 1H), 1.27 – 1.10 (m, 6H), 0.88 (s, 9H), 
0.07 – 0.02 (m, 6H). LRMS (ESI) m/z calcd for C26H43NO3SiNa+ [M+Na]+ 468.3, found 468.1. 
 
Scheme 3.13.4: Synthesis of (2R,E)-7-((tert-butyldimethylsilyl)oxy)-N-((1R,2R)-1-hydroxy-1-
phenylpropan-2-yl)-N,2-dimethyl-2-vinyloct-5-enamide (S3) 
Diisopropylamine (18.62 µL, 0.133 mmol) was added via syringe to a suspension of LiCl 
(14.98 mg, 0.353 mmol) in THF (105 µL) at -78 °C. A solution of n-BuLi (76 µL, 0.122 mmol, 
1.6 M in THF) was added via syringe, and the resulting mixture was warmed to 0 °C. After 5 min, 
the resulting solution was cooled to -78 °C. An ice-cooled solution of S2 (26.2 mg, 0.059 mmol) 
in THF (175 µL) was added via cannula. The transfer was rinsed with additional THF (70 µL), and 
the resulting mixture was warmed to 0 °C. After 1 h, the reaction mixture was cooled to -40 °C, 
and DMPU (17.8 µL, 0.148 mmol) was added via syringe. After 10 min, the reaction mixture was 
cooled to -60 °C, and iodomethane (27.4 µL, 0.441 mmol) was added slowly via syringe. After 5 
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min, the reaction mixture was warmed to -50 °C. After 42 h, saturated NH4Cl (1 mL) was added 
to quench the lithium alkoxide salts, and the resulting biphasic mixture was allowed to warm to rt. 
Brine (10 mL) and DCM (12.5 mL) were added, and the layers were seperated. The aqueous layer 
was further extracted with DCM (3 x 12.5 mL). The combined organic layers were dried over 
anhydrous MgSO4, were filtered, and were conc. in vacuo. The crude product was purified via 
flash column chromatography to yield the pure product S3. 1H NMR (400 MHz, CDCl3) δ 7.43 – 
7.27 (m, 5H), 6.11 – 4.18 (m, 7H), 2.98 – 2.67 (m, 3H), 2.04 (s, 2H), 2.00 – 1.59 (m, 3H), 1.38 – 
0.93 (m, 10H), 0.88 (s, 9H), 0.21 – -0.10 (m, 6H). LRMS (ESI) m/z calcd for C27H45NO3SiNa+ 
[M+Na]+ 482.3, found 482.3. 
 
Scheme 3.13.5: Synthesis of (2R,E)-7-hydroxy-N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-
N,2-dimethyl-2-vinyloct-5-enamide (S4) 
To a 15 mL falcon tube (plastic) under N2 was added S4 (47.6 mg, 0.104 mmol) in THF 
(2.96 mL). The reaction mixture was stirred, vented with N2, and cooled to 0 °C before adding HF-
pyridine (0.597 mL, 0.104 mmol) dropwise via syringe. The reaction was stirred for 2 hours at 0 
°C, warmed to rt, and stirred for an additional 2 hours at rt. The reaction was cooled down to 0 °C 
again, quenched with saturated NaHCO3 (30 mL) added dropwise over 10 min (moved to larger 
plastic vial halfway through quenching), and diluted with 30 mL EtOAc. The organic layer was 
seperated, and the aq layer was backextracted with EtOAc (2 x 20 mL). The combined organic 
layers were washed with CuSO4 (0.1 M, 15 mL) and H2O (15 mL). The organic layer was dried 
with MgSO4, filtered and conc. in vacuo to yield a crude, yellow-tinted oil, S4 (31.1 mg, crude 
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weight). This material was used without any further purification directly in the next reaction step 
(Scheme 3.13.6). LRMS (ESI) m/z calcd for C21H31NO3Na+ [M+Na]+ 368.2, found 368.3. 
 
Scheme 3.13.6: Synthesis of (2R,E)-2-methyl-2-vinyloct-5-ene-1,7-diol (196) 
To a small, flame-dried vial under N2 was added THF (421 µl) via syringe, and the solvent 
was cooled to -78 °C. Next diisopropylamine (53.1 µl, 0.379 mmol) and n-BuLi (219 µl, 0.350 
mmol, 1.6 M in THF) were added sequentially via syringe. The resulting yellow solution was 
stirred at -78 °C for 10 min, then at 0 °C for 5 min (ice-water bath). Borane-ammonium complex 
(12.4 mg, 0.362 mmol) was added quickly (remove septa and add) and the contained was resealed. 
The reaction was ran, worked up, and purified following a previously published methodology with 
LAB,39 and 196 was isolated. 1H NMR (401 MHz, CDCl3) δ 5.79 – 5.37 (m, 3H), 5.18 (dd, J = 
10.9, 1.3 Hz, 1H), 5.06 (dd, J = 17.6, 1.3 Hz, 1H), 4.25 (p, J = 6.4 Hz, 1H), 3.37 (q, J = 10.8 Hz, 
2H), 1.97 (dq, J = 16.6, 5.9 Hz, 2H), 1.51 – 1.34 (m, 4H), 1.24 (d, J = 6.3 Hz, 3H), 1.02 (s, 3H); 
LRMS (ESI) m/z calcd for C11H20O2Na+ [M+Na]+ 207.1, found 207.1. 
 
Scheme 3.13.7: Synthesis of (R,E)-2-methyl-7-oxo-2-vinyloct-5-enal (182) 
To a small vial (oven-dried) was added (2R,E)-2-methyl-2-vinyloct-5-ene-1,7-diol (6.2 mg, 
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0.034 mmol) in DCM (1.35 mL) which was stirred, put under N2, and cooled to 0 °C with an ice 
bath. The septa was removed, the starting material was added quickly, and the mixture was resealed 
and put under N2 again. The mixture was stirred at 0 °C for 5 min and at room temperature for 1 h 
50 min. Additional DMP (7.0 mg) in DCM (0.25 mL) was added, and the reaction was stirred for 
an additional 30 min, before the sample was concentrated in vacuo. The crude material was 
purified through a short column of silica gel (hexanes/EtOAc, 75/25) to yield the pure product 182. 
1H NMR (500 MHz, CDCl3) δ 9.39 (s, 1H), 6.77 (dt, J = 16.0, 6.7 Hz, 1H), 6.08 (dt, J = 15.9, 1.6 
Hz, 1H), 5.77 (dd, J = 17.6, 10.8 Hz, 1H), 5.33 (dd, J = 10.8, 0.6 Hz, 1H), 5.17 (dd, J = 17.6, 0.6 
Hz, 1H), 2.24 (s, 3H), 2.21 – 2.14 (m, 2H), 1.79 – 1.73 (m, 2H), 1.22 (s, 3H); LRMS (ESI) m/z 
calcd for C11H16O2Na+ [M+Na]+ 203.1, found 203.1. 
 
Scheme 3.13.8: Synthesis of (2R,E)-7-((tert-butyldimethylsilyl)oxy)-N-((1R,2R)-2-hydroxy-
1,2-diphenylethyl)-N-methyl-2-vinyloct-5-enamide (194) 
2,2,6,6-tetramethylpiperidine (0.398 mL, 2.34 mmol) was added via syringe to a suspension 
of lithium chloride (258 mg, 6.09 mmol) in THF (1.12 mL) at -78 °C. A solution of n-BuLi (1.31 
mL, 2.09 mmol, 1.6 M in THF) was added via syringe, and the resulting mixture was warmed to 
0 °C. After 20 min, an ice-cooled solution of 19333 (300 mg, 1.02 mmol) in THF (2.79 mL) was 
added via cannula. The rbf and cannula were rinsed with additional THF (2 x 0.47 mL; 1 x 1.00 
mL). After 15 min, the reaction mixture was cooled to -78 °C. After 5 min, 192 (691 mg, 2.03 
mmol) was added via syringe, followed by a rinse with THF (50 μL). After 40 min, the reaction 
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was warmed to 0 °C. After 4.5 h, saturated NH4Cl solution was added to quench the lithium 
alkoxide salts, and the reaction mixture was let warm to rt. 
Brine and ethyl acetate were added, and the layers were separated. The aqueous layer was 
further extracted with ethyl acetate (2x). The combined organic layers were dried over MgSO4, 
filtered, and concentrated under vacuo. The crude product was purified via flash column 
chromatography (70/30, hexanes/EtOAc) to yield a clear, colorless, highly-viscous liquid product 
194 (326 mg, 63% yield). 1H NMR (400 MHz, CDCl3) δ 7.61 – 7.07 (m, 10H), 5.91 – 4.96 (m, 
7H), 4.26 – 4.02 (m, 1H), 3.33 – 3.08 (m, 1H), 2.97 – 2.80 (m, 3H), 2.13 – 1.07 (m, 8H), 1.03 – 
0.73 (m, 9H), 0.04 (s, 3H), 0.02 (s, 3H); HRMS (ESI) m/z calcd for C31H45NO3SiH+ [M+H]+ 
508.3241, found 508.3240; HRMS (ESI) m/z calcd for C31H45NO3SiNa+ [M+Na]+ 530.3061, found 
530.3060. 
 
Scheme 3.13.9: Synthesis of (2R,E)-7-((tert-butyldimethylsilyl)oxy)-N-((1S,2S)-2-hydroxy-
1,2-diphenylethyl)-N,2-dimethyl-2-vinyloct-5-enamide (195) 
Diisopropylamine (0.185 mL, 1.32 mmol) was added via syringe to a suspension of LiCl 
(149 mg, 3.51 mmol) in THF (1.04 mL) at -78 °C. A solution of n-BuLi (0.76 mL, 1.21 mmol, 1.6 
M in THF) was added via syringe, and the resulting mixture was warmed to 0 °C. After 5 min, the 
resulting solution was cooled to -78 °C. An ice-cooled solution of 194 (297 mg, 0.584 mmol) in 
THF (1.74 mL) was added via cannula. The transfer was quantitated with additional THF (348 µL) 
and a second portion of THF (348 µL), and the resulting mixture was warmed to 0 °C. After 1 h 
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(at 0 °C), the reaction mixture was cooled to -40 °C, and DMPU (177 µL, 1.47 mmol) was added 
via syringe. After 10 min, the reaction mixture was cooled to -60 °C (via addition of dry ice to 
cryocool), and iodomethane (273 µL, 4.38 mmol) was added slowly via syringe. After 5 min, the 
reaction mixture was allowed to warm to -50 °C (set on cryocool, not an instant change). After 42 
h, saturated aqueous ammonium chloride (3.0 mL) was added to quench the lithium alkoxide salts, 
and the resulting biphasic mixture was allowed to warm to rt. Brine (20 mL) and DCM (25 mL) 
were added, and the layers were seperated. The aqueous layer was further extracted with DCM (3 
x 25 mL). The combined organic layers were washed again with Brine (50 mL), backextracted 
aqueous Brine with DCM (25 mL), and final combined organic layers were dried over anhydrous 
MgSO4, filtered, and conc. in vacuo. The crude material (Rf [starting material] = 0.25 
[hexanes/EtOAc, 80/20]; Rf [product] = 0.295 [hexanes/EtOAc, 80/20]) was purified via flash 
column chromatography (hexanes/EtOAc, 85/15 to 80/20) to yield the pure product 195 (223 mg, 
73% yield). 1H NMR (500 MHz, CDCl3) δ 7.53 – 7.01 (m, 10H), 6.00 – 5.79 (m, 1H), 5.76 – 5.55 
(m, 1H), 5.55 – 5.28 (m, 3H), 5.15 – 4.92 (m, 2H), 4.23 (p, J = 6.0 Hz, 1H), 2.85 (s, 3H), 2.04 – 
1.54 (m, 5H), 1.24 (s, 3H), 1.20 – 1.14 (m, 3H), 0.89 (s, 9H), 0.19 – -0.11 (m, 6H); LRMS (ESI) 
m/z calcd for C32H47NO3SiNa+ [M+Na]+ 544.3, found 544.1. 
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